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Hyperoxia Treatment Triggers Cognitive Impairment in Alzheimer’s Transgenic Mice
April A Cox
ABSTRACT
An association between major surgery in the elderly and precipitation of Alzheimer’s
disease (AD) has been reported. Hyperoxia (100%) oxygen is commonly administered
after surgery to increase the oxygen content of blood. However, hyperoxia is a potent
cerebral vasoconstrictor and generator of free radicals, as is β-amyloid (Aβ). This study
was aimed at examining behavioral, neuropathological, and neurochemical effects of
hyperoxia treatments in APPsw transgenic mice (Tg+), which have elevated brain Aβ
levels by 3-4 months of age but are not yet cognitively-impaired. At 3 months of age,
Tg+ mice were pre-tested in the radial arm water maze (RAWM) task of working
memory and found to be unimpaired. At 4.5 months of age, half of the Tg+ mice
received the first of 3 equally-spaced hyperoxia sessions (3 hrs each) given over the
ensuing 3 months. The other half of the Tg+ mice were exposed to compressed air
during these 3 sessions. RAWM testing performed immediately following the final gas
session at 7.5 months of age revealed significant working memory impairment in Tg+
mice exposed to hyperoxia. The Tg+ group that was exposed to placebo treatment
showed a trend towards impairment, however, was not significantly different from the
non-transgenic group. Hyperoxia-induced memory impairment in Tg+ mice did not
involve changes in brain Aβ deposition, degenerative cell numbers in hippocampus,
neocortical lipid peroxidation, or hippocampal levels of APP, ApoE, COX-2, or GFAP.
The combination of excess Aβ and hyperoxia could have induced greater oxidative stress
and cerebral vasoconstriction than either one alone, resulting in a pathologic cerebral
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hypoperfusion that triggered subsequent cognitive impairment. These results suggest that
humans genetically pre-disposed to AD and those with increased brain Aβ levels have
increased risk of developing cognitive impairment following hyperoxia treatment and
cast doubt on the wide spread use of hyperoxia in aged individuals at risk for developing
AD.
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Alzheimer’s Disease Background
Alzheimer’s disease can be described as a “disease of the brain that results in an
illness of the mind” (Martin et al., 2002).

The term Alzheimer’s Disease (AD), first

discovered by Alois Alzheimer in 1906, is marked by severe memory loss as well as an
array of both psychological and physical symptoms. The primary risk factor for
developing AD is age. As humans progressively have longer life spans it is not,
therefore unexpected to also see a dramatic rise in the prevalence of the disease. In the
year 2000 there were approximately 4.5 million diagnosed persons with AD in the US, by
the year 2050 it is estimated that there will be 13.2 million persons with AD (Herbert et
al., 2003).
AD has been under study for over a century, yet, there is still a profound lack of
understanding as to the exact molecular mechanisms underlying the disease. Research
has lead to the identification of genetic mutations responsible for the early onset form of
AD. These mutations have provided a great deal of insight into some of the underlying
causes of the disease as well as provide researchers with various animal models. While
there are currently several different treatments designed to slow the progression of the
disease, none of the current treatments have been able to provide a cure for this
debilitating disease. Hopefully, with further research and a better understanding of the
disease a cure will soon be in sight.
Behavioral Characterization
AD has become synonymous with the general public as a disease primarily
marked by memory loss. However, the disease encompasses an array of behavioral
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symptoms such as paranoia, confusion, disorientation, loss of mental competence, and
difficulty in understanding language (Martin et al., 2002). The symptoms of AD are
highly dynamic. Symptoms emerge and evolve at different rates and at different stages
of the disease. While there is a large degree of variation in the symptoms an individual
might be faced with, the disease does follow a predictable sequence of progression.
Currently, it is commonly believed that pathological changes associated with AD
begin many years prior to the manifestation of clinical symptoms, this time is termed the
latent period. The earliest observable behavioral symptom is an impairment in short-term
(working) memory. Short-term memory is defined as the memory used to recall
information that persists for only a few minutes after being exposed to the memory
encoding stimuli. This early loss of memory coincides with studies that suggest the
hippocampus and entorhinal cortex are the first brain areas to be affected by the
neurofibrillary pathology, areas that are believed to be important in new memory
formation (Braak & Braak, 1991). A patient who only suffers from short-term (working)
memory impairment and who retains the ability to perform everyday tasks can be
classified as being in the pre-dementia stage (Nestor et al., 2004). This stage has also
been termed mild cognitive impairment (MCI). The underlying concept of MCI is that it
represents the earliest perceptible stage of AD (Nestor et al., 2004). Thus, a patient with
a diagnosis of MCI would be considered at high risk for the development of AD.
However, currently due to a lack of homogeneity in the clinical testing and evaluation of
MCI, a diagnosis does not fully correlate with an eventual development of AD. There is
an obvious need for researchers to more precisely define this stage of AD as it has been
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suggested that the MCI stage might be an optimal time to intervene with drug treatment
(Voisin et al., 2003).
The time course of progression of MCI to AD is extremely variable. As
mentioned earlier the first symptom to appear is a deficit in short-term memory that can
begin at least 5 years prior to disease diagnosis. Deficits in semantic memory (ability to
recognize words, faces, and objects), attentional processes, and executive functions
slowly begin to emerge in a patient who is in the pre-diagnosis stage (Nestor et al., 2004).
When these deficits become widespread and severe enough to interfere with a patients
normal life, and the criteria for a diagnosis of AD are met as set by various groups ( for
example, American Psychiatric Association’s Diagnostic and Statistical Manual of
Mental Disorders), a patient would be then officially diagnosed with early stage AD
(Nestor, 2004). Neuropsychiatric symptoms also begin to emerge during the early and
moderate stages of AD. The most common symptoms include depression, apathy, and
irritability (Hart et al., 2003). Also, but less frequently patients experience
hallucinations, elation, and disinhibition (Hart et al., 2003). A diagnosis of moderate
stage of AD is normally given to a patient whose symptoms have progressively worsened
and who also starts to suffer from language deficits and a long term memory loss. The
time frame of progression varies among individuals with some patients progressing from
early to end stage AD in only a few years and others living with the diagnosis for 10-20
years. The late or advanced stage of AD is marked by a very severe loss of memory and
cognitive functions, and a severe loss of motor skills. In end stage AD a patient would
be in a semi-vegetative bedridden state, death would most likely result from illness.
Pathology
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The complexity of the underlying pathological mechanisms causing AD can be
attested to the fact that after nearly 100 years of research into the disease there still is not
a complete understanding. Currently, the pathological hallmarks of the disease include:
neuritic plaques, neurofibrillary tangles (NFT’s), loss of cholinergic function, widespread
neuronal loss and synaptic modifications in the cortex, hippocampus and other brain
areas responsible for memory and cognition (Parihar et al., 2004). There is much debate
over the exact relationship among these pathologies. It has been firmly established that
neuritic plaque formation precedes neurofibrillary formation in cortical areas (Vickers et
al., 2000). Also, it has been established that pathologies begin developing as far as
twenty years before the onset of clinical symptoms during the latent period.
One of the first changes the brain would undergo during the latent period is a
reduction in viable acetycholine receptors (Kihara et al., 2004). More specifically, the
M1, M2 and M4 subtypes of muscarinic acetycholine receptors have all been reported to
be decreased in AD (Volpicelli et al., 2004). The functioning of the M1 receptors
subtype is thought to be down-regulated in AD and treatment with M1 receptor agonists
has shown positive results (Fisher et al., 2000) The loss of activity in the cholinergic
system is a target point for many pharmaceutical therapies. Second to a loss of
acetycholine receptors, the brain begins to develop and accumulate β-amyloid (Aβ)
plaques. The plaques consist of extracellular deposits of Aβ arranged in a star-shaped
mass with a compact core. The Aβ that comprises the plaque is a byproduct that results
from cleavage events to the larger parent protein; amyloid precursor protein (APP).
APP is a transmembrane protein that is found in the endoplasmic reticulum and is
posttranslationally modified through the secretory pathway to yield several different
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peptides (Selkoe, 2001). The major secreted derivative of APP is α-APPs a result of
cleavage by α-secretase 12 amino acids away from the NH2 terminal (Selkoe, 2001).
There have been a number of suggestions made as to the exact functioning of the α-APPs
in a normal physiological state. Researchers have proposed that the α-APPs peptide may
act as an autocrine factor or as a neuritotrophic factor. The deletion of the APP gene does
not confer early mortality or high morbidity suggesting that other homologous proteins
may assume whatever role the α-APPs plays (Selkoe, 2001).
In an alternate toxic form of APP processing, the toxic Aβ protein can be formed.
First, the enzyme β-secretase cleaves the APP protein at the N-terminus amino acid 671.
Then a second enzyme, γ-secretase cuts the remaining larger fragment of the APP protein
at amino acid 711 or 713 to produce the Aβ40 or Aβ42 fragment (Tamagno et al., 2002).
The Aβ fragments then begin to aggregate together to form first into dimers and
oligomeric isoforms. Then as aggregation continues the fragments form diffuse plaques
and then finally compact plaques. Activated glial cells such as microglia and astrocytes
will surround the amyloid plaques in response to their formation and produce toxins such
as inflammatory cytokines that lead to further neurodegeneration (Mattson et al., 2004).
There is also some evidence that activated microglia can clear Aβ deposits (Jantzen et al.,
2002). Aβ 1-40 is the major species produced, however, the Aβ 1-42 is less soluble and
aggregates more readily (Veurink et al., 2003). These plaques are found most notably in
the hippocampus and the association cortices. Another key protein, apolipoprotein E
(apoE) plays a vital role in the formation of neuritic plaques. While the exact mechanism
is still unknown, studies done with transgenic mice have found that the presence of apoE
is necessary in the formation of plaques (Marques et al., 2004). Current research is
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focused on the role of proteolytic fragments in the formation of plaques. The exact time
course for the formation of a neuritic plaque is unknown. However, it is widely accepted
that the process occurs rather slowly.
The accumulated Aβ42 in plaques then begins to release diffusible oligomers of
the Aβ42 and protofibrils that are thought to have adverse affects on neighboring cells
(Selkoe, 2001). Dendritic loss, neuronal death, and dystrophic neurites are often found
within and surrounding the plaques. This cellular damage is thought to be a result of the
increased oxidative stress seen around plaques. Studies have shown that Aβ can induce
the formation of oxygen dependent free radicals that lead to lipid and protein oxidation
(Veurink et al., 2003). The formation of free radicals centered around Aβ plaques results
in areas of increased oxidative stress.
The term oxidative stress is a general term used to describe the level of oxidative
damage being caused by oxidants, such as reactive oxygen species (ROS) and reactive
nitrogen species (RNS), to the surrounding cells and tissues (Emerit et al., 2004).
Oxidative stress occurs when the production of oxidants exceeds the antioxidant
capabilities of the cell (Maccioni et al., 2001). ROS, such as the superoxide (O-) free
radical are formed as normal byproducts of metabolic reactions, such as the energy
generating reactions that occur in the mitochondria. Oxygen is the primary source of free
radicals in aerobic organisms, and exposure to hyperoxia (>21% Oxygen) increases the
production of free radicals (Reiter et al., 1998). The role that oxidative stress plays in the
pathogenesis of AD has been widely explored. The AD brain has been found to overproduce ROS and NOS, both of which are implicated in cellular damage and apoptosis
(Maccioni et al., 2001). Studies have found that the AD brain has increases in lipid
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peroxidation, decreases in polyunsaturated fatty acids, increases in 4-hydroxynonenal (an
aldehyde product of lipid peroxidation), and increases in protein and DNA oxidation; all
of which are evidence of oxidative stress (Markesbery et al., 1997). Oxidative stress
plays a pivotal role in disrupting cellular functions such as, ion transport, calcium
mobilization, and excitotoxicity and inducing apoptosis in neurons, astrocytes and
microglia (Emerit et al., 2004). Excitotoxicity, the process by which excess glutamate
over-activates glutamate receptors resulting in intracellular calcium overload with
subsequent neural cell death, is seen in the AD brain and is closely linked with oxidative
stress (Facheris et al., 2004). The exact source of the increased oxidative stress seen in
the AD brain is not yet fully known. However, one study suggested that it may result
from the mitochondrial dysfunction induced by the presence of Aβ, and by glial
activation (Emerit et al., 2004). It is widely accepted that oxidative stress is an early
event in AD and most likely plays an active role in the pathogenesis of the disease
(Practico et al, 2002).
The damage caused by Aβ accumulation and oxidative stress to neighboring cells
triggers an inflammatory response. One of the first inflammatory responses seen is
activated microglia and their cytokine release (Selkoe, 2001). Specifically, microglia
exposed to Aβ secrete pro-inflammatory cytokines interleukin-1β (IL-1 β), interleukin-6
(IL-6), and tumor necrosis factor α (TNFα) (Tuppo et al., 2005). The release of these
cytokines in turn attracts astrocytes which in turn release the additional inflammatory
proteins ACT and ApoE (Selkoe, 2001). Astrocytes clustered around Aβ plaques have
been shown to secrete chemokines, cytokines, and reactive oxygen species that may
contribute to the neuronal damage seen surrounding Aβ plaques (Johnstone et al., 1999).
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In addition to secreting cytokines and stimulating astrocytes, microglia also appear to
play a role in Aβ clearance. Activated microglia have been shown to actively
phagocytize and clear Aβ away from deposition sites (Rogers et al., 2001).
The inflammatory response seen in the brain after the accumulation of Aβ plaques
is thought to play a pivotal role in the cascade of pathological changes seen in the AD
brain, including accentuation of NFT formation. This idea has been coined the amyloid
cascade hypothesis and has been overwhelmingly the most popular current concept for
the explanation of AD. However, there are researchers who challenge the amyloid
hypothesis.
One of the biggest pieces of evidence that researchers who oppose the amyloid theory
use is the concept that Aβ levels have little predictive value for the cognitive state of the
patient (Lee et al., 2004). They also use the premise that studies used to formulate the
amyloid theory were done in cell culture models and that they are not good indicators of
in vivo processes.

As an alternate theory researchers have been suggesting for years that

Aβ does not function as the disease-causing pathogenic agent, but rather Aβ plays a
protective role in the brain (Lee et al., 2004). A recent study found that Aβ functions as
an endogenous regulator of neuronal activity (Esteban et al., 2004). There has been
growing evidence that points towards the antioxidant capabilities of Aβ as demonstrated
by its ability to prevent lipoprotein oxidation in the CSF (Kontush et al., 2001). Aβ’s
ability to bind and chelate Cu is the most likely mechanism through which it reduces
oxidative stress (Atwood et al., 2003). These findings are in accord with earlier work
that has found Aβ plaque load to be inversely correlated with oxidative stress (Nunomura
et al., 2001). Thus, oxidative stress triggers Aβ generation in an attempt to decrease the
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oxidative stress load (Atwood et al., 2003). Individuals with high Aβ plaque loads that
remain cognitively normal may be regarded as showing a healthy response to the
oxidative stress encountered during ageing. Researchers in favor of viewing Aβ as a side
effect, rather than causative agent of the disease also acknowledge the toxic properties of
the protein. They propose that at high enough oxidative stress burdens Aβ begins to
accumulate and results in uncontrollable plaque growth with the subsequent toxic effects
mentioned above (Atwood et al., 2003). This theory, in sharp contrast to the amyloid
cascade hypothesis, calls into question the wide spread use of therapeutic strategies
aimed at reducing Aβ loads.
NFTs, the second hallmark lesion of AD, are intracellular aggregates composed of
the microtubule associated tau protein (Dickson et al., 2004). NFT’s form as a result of
hyperphosphorlyation of the tau protein at several different residues. The
phosphorylation of the tau protein leads to a dissociation from the microtubules and
eventual aggregation into paired helical filaments (Rosenberg et al., 2000). These
tangles can be found in numerous brain regions including: hippocampus,
parahippocampal gyrus, amygdala, frontal, temporal and occipital association cortices
(Selkoe, 2001). NFTs are also found in numerous other neurodegenerative disorders
(Kuf’s disease, subacute sclerosing panencephalitis, etc), and in the brains of aged nondemented individuals (Gomez-Ramos et al., 1998). There is evidence that suggests Aβ
plays a causative role in the formation of neurofibrillary tangles (NFTs). However, the
exact relationship is still uncertain. The fact that NFTs can arise in the absence of betaamyloid deposition suggests that tangles can form as a result of a variety of neuronal
conditions.
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Currently, there are many different theories as to the exact etiopathology that
induces the formation of NFT’s in AD. One of these theories of NFT formation has
arisen by examining the brains from pre-diagnosed AD patients. Researchers have found
that the pathologies associated with Aβ plaques very closely resembles structural damage
to the axons of neurons (Vickers et al., 2000). The structural damage to the axons caused
by the accumulation of Aβ early in the disease may trigger an inflammatory response in
the brain that becomes prolonged and results in the formation of NFT’s (Vickers et al.,
2000). The degree of cognitive impairment in an AD patient correlates more closely with
the amount and distribution of NFT’s than with the amount of Aβ deposited in the brain
(Bennett et al., 2004). This finding puts an increased emphasis on the role that NFT’s
play in the progression of AD.
During the course of AD progression a patient would also expect to see a
substantial decrease in brain volume. This global volume loss is due to many factors;
death of neurons, gyri shrinking, widened sulci, and loss of synapses.
Genetics
Alzheimer’s disease can be subdivided into two main groups: familial and
sporadic. Familial AD (FAD) accounts for approximately 10% of all cases and is
characterized by known genetic mutations and a much earlier age of onset. Symptoms
can arise in patients with FAD as early as 40 years of age but generally occur no later
than 60 years of age. Phenotypically, familial AD is almost indistinguishable from
sporadic AD, except for the fact that some forms of familial AD have a more rapid
progression than the sporadic forms. Sporadic AD accounts for approximately 90% of all
cases and is distinguished by a late age of onset. Sporadic AD also has an associated
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genetic mutation that has been discovered, the ApoE4 allele, that will be discussed in
detail later. This mutation does not definitively confer development of AD but persons
carrying the gene are considered to be at a much higher risk. Age of onset varies greatly
in the sporadic form of AD, ranging from 65-90 years old. Once a person reaches 90
their chances of developing AD drops dramatically.
The first genetic mutation that was discovered in the familial form of AD was a
mutation in the gene coding for APP (Selkoe, 2001). There are 16 known pathogenic
mutations and 4 nonpathogenic mutations in the APP gene (Zekanowski et al., 2004).
Mutations result in changes in the peptide sequence located next to the β-secretase and γsecretase cleavage sites. These changes in sequence, although subtle, are thought to have
a major affect on the proteolytic cleavage of the protein. The double Swedish mutation
(K670N/M671L), a mutation isolated from a family from Sweden, affects β-secretase
activity and results in elevated levels of Aβ40 and Aβ42 (Zekanowski et al., 2004). The
London mutation affects the activity of γ-secretase, resulting in elevated levels of both
Aβ40 and Aβ42 , with the greatest increase seen in Aβ42 . In general, families carrying AD
pathogenic mutations of APP develop symptoms in their fifties. APP mutations only
account for 4-6% of the familial form of AD (Zekanowski, 2004). These mutations have
helped provide more evidence for the amyloid cascade hypothesis.
APP gene dosage has proven to be another key piece of evidence for researchers
supporting the amyloid hypothesis. The effects of the location of the APP gene on allele
21 is clearly seen in patients with down’s syndrome. An individual with trisomy 21 can
expect to see identical neuropathology as compared with AD due to the increased gene
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expression seen with an extra copy of the APP gene. Individuals identified with this
mutation often have AD onset during their 50’s (Selkoe, 2001).
The most common genetic mutation resulting in FAD are those found in
presenilin 1 genes (PS1) and presenilin 2 genes (PS2) (Zekanowski et al., 2004). While
the exact functions of the PS1 and PS2 genes are not clear, there is growing evidence that
suggests they both may serve as the active sites of the γ-secretase complex (Zekanowski
et al., 2004). The mutations directly affect APP processing, resulting in increased
amounts of Aβ42, and providing even more evidence for the amyloid cascade hypothesis.
Currently, there have been more than 100 mutations identified in the PS1 gene and only 9
in the PS2, with nearly all being missense mutations located around the transmembrane
domains of the proteins (Zekanowski et al., 2004). Animal models of APP mutations
crossed with animals models carrying the PS1 mutation yield animals with dramatically
increased levels of Aβ plaques. The fact that presenilin mutations result in increased Aβ
levels further supports the amyloid cascade hypothesis.
Diagnosis
The tools and techniques used in the diagnosis of AD are advancing as fast as
technology and knowledge of the disease permits. For detecting the early form of AD, a
test must be able to accurately discriminate between pathological processes and normal
ageing, as well as other neurological disorders that may cause memory loss (Nestor,
2004). The diagnosis of AD is commonly based on the criteria put forward by the
National Institute of Neurologic and Communicative Disorders and Stroke-Alzheimer’s
Disease and Related Disorders Association (NINCDS-ADRDA) (Cummings, 2004).
According to the NINCDS-ADRDA there are three levels of diagnosis: definite (clinical
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diagnosis with histological confirmation), probable (typical clinical syndrome without
histological confirmation) or possible (atypical clinical syndrome but no alternative
diagnosis apparent without histological confirmation) (Cummings, 2004).
A patient who initially presents themselves with dementia as a candidate for early
AD would first go through a battery of tests ruling out other dementia causing diseases
such as syphilis, AIDS, inflammatory diseases or exposure to dementia-inducing toxins
(Cummings, 2004). After ruling out other causes of dementia, a patient would most
likely begin cognitive testing. The most common cognitive test given is the Mini-Mental
State Exam (MMSE). Psychological testing is required for a clinical diagnosis of AD
and can help the physician determine the progression of the disease. Up until very
recently, psychological testing alone was considered adequate to provide enough
evidence for a diagnosis of AD. Psychological testing does have its weaknesses. One
weakness is the high variability in performance seen in the normal human population,
which can result in test scores not indicative of cognitive status. The tests themselves can
be biased, and norms are established from pools of people not necessarily indicative of
the population at large (Zamrini et al., 2004). Other approaches using biological
markers or neuroimaging eliminate the pitfalls seen in psychological screening of AD
patients.
The most researched biological markers used to diagnose AD are Aβ proteins and
levels of total and phosphorylated tau. Aβ is generated in all individuals from normal
APP metabolism and is secreted in the extracellular space allowing for its detection in
both the cerebral spinal fluid (CSF) and blood plasma (Seubert et al., 2002). The
majority of studies have found a decrease in the amount of Aβ42 in the CSF of AD
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patients (Sobow et al., 2004). However, the use of decreased levels of Aβ42 is not a
definitive diagnosis of AD alone since decreased levels of Aβ42 have also been found in
patients with depression and other dementias (Andreasen et al., 2001). Numerous studies
have found increased amounts of both normal and phosphorylated tau in the CSF of AD
patients (Sobow et al., 2004). The combination of analyzing the ratio of normal tau to
Aβ42 has proven to be the most effective tool in using biological markers in the diagnosis
of AD (Gomez-Tortosa et al., 2003). The accuracy of using these biological markers
alone in diagnosing AD is widely questioned. However, the analysis of biological
markers can greatly help in an AD diagnosis when paired with other diagnostic
techniques such as brain imaging.
A landmark announcement by Medicare in June, 2004 stated that it will be
providing coverage for brain scans in order to help confirm diagnosis of AD. Scientists
have known for years that many different imaging techniques including positron emission
tomography (PET), magnetic resonance imaging (MRI) and computer tomography (CT)
scans can help tremendously in confirming AD. Also, due to the fact that AD begins
decades prior to psychological symptoms, imaging studies may provide doctors with a
tool for diagnosing AD in the very beginning stages. Neuroimaging can provide doctors
with not only preclinical disease state, but also rate of disease progression if imaging
studies are done in series (Zamrini et al, 2004). The implications of being able to
diagnose a patient 20 years prior to disease onset are astounding in that it opens the door
for possible prevention therapeutics to be utilized.
Both structural and functional neuroimaging techniques offer insight into disease
progress and diagnosis. Structural imaging uncovers anatomical changes that are
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occurring in the brain prior or during disease pathogenesis. Imaging studies recently
have shown that atrophy in the medial temporal lobe shows very high predicted cognitive
decline (Fox et al., 2004). Longitudinal studies have shown that the severity of AD
correlated with rates of hippocampal volume loss (Zamrini et al., 2004). Neuroimaging
of structural changes that occur not only give researchers insight into the disease
pathogenesis, but also may provide a tool that can accurately assess an individual’s risk
for developing AD.
Functional imaging may offer an even more accurate way to diagnose AD. The
most common way researchers measure cerebral activity is through Positron Emission
Tomography (PET). PET scanning works by injecting the patient with a small amount
of tracer drug that attaches itself to a variety of energy sources, most often 2deoxyglucose (2DG). The 2DG, tagged with a positron emitting isotope, will accumulate
in areas that are more active than others. The tracer isotope emits positrons, that collide
with electrons nearby, resulting in gamma rays that are picked up by sensors and mapped
onto different brain regions showing areas of high activity, and also more importantly in
the case of diagnosing AD, areas of low activity. A patient suspected of having AD will
show a dysfunction or reduced brain activity (low 2DG levels) in temporo-parietooccipital cortices on a PET scan (Nestor et al., 2004).
Another interesting imaging technique that has emerged in the last year is a
technique using a novel amyloid-imaging PET tracer, called Pittsburgh Compound-B
(PIB) (Klunk et al., 2004). A study done recently involved tracing amyloid deposition in
16 patients showed that PIB retention was increased primarily in the association cortex,
an area known to contain large amyloid load in AD patients (Klunk et al., 2004). This
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new imaging technique may provide researchers with a tool to quantify amyloid load in
living patients. Also, the technique has the ability to monitor the effects of drugs
designed to limit amyloid deposition.
In addition to PET scanning, another technique, Single-Photon Emission
Computed Tomography (SPECT) is also used in functional imaging studies.

The basic

idea behind SPECT scanning is the same to PET scanning. Only SPECT scanning
utilizes a radioactive compound that is injected into the patient. Regions with higher
activity show an increased signal that is mapped onto brain regions. SPECT scans have
also helped to provide more evidence for the argument that MCI is an antecedent to AD.
A study using SPECT scanning techniques revealed that patients diagnosed with MCI
who showed a hypoperfusion in the posterior cingulated cortex later converted to AD
(Nestor et al., 2004). Findings such as these are greatly improving the accuracy of AD
diagnosis.
Scanning techniques offer a promising tool for a more accurate, earlier detection
of AD. However, due to the nature of the disease, it is still essential to perform cognitive
testing. Brain imaging techniques, alongside cognitive testing and biological marker
analysis can provide doctors with a powerful tool in the diagnosis of AD.
Risk Factors
The only known genetic inheritance that is considered to be a risk factor for
developing sporadic AD is the ε4 allele of the apolipoprotein gene. Apoliprotein (ApoE)
has three alleles, ε2, ε3, and ε4.

ApoE is involved in a number of functions including

cholesterol transport, dendritic growth, neuronal repair and it has possible antiinflammatory functions (Lahiri et al., 2004). Individuals who are homozygous for the
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ApoE4 allele of the protein would be considered at a higher risk for the eventual
development of AD and account for 10-15% of AD cases (Zekanowski et al., 2004).
However, only one third of people who inherit these alleles develop AD illustrating
further the complexity of factors involved with the disease. Inheritance of the ε4 allele of
ApoE results in increased amyloid accumulation, neurotoxicity, and increased oxidative
stress (Lahiri et al., 2004). While this is the only widely documented genetic inheritance
associated with an increased occurence of sporadic AD, researchers believe that most
likely mutations in as many as 50 other genes could act as risk factors (Zekanowski et al.,
2004). Although these genes have yet to be discovered, the fact that first degree relatives
of sporadic AD patients are considered to be at a higher risk helps provide evidence that
genetics may play a larger role than what is currently known.
The primary risk factor for AD is aging, which is unavoidable. Interestingly, an
individuals’ risk for developing AD will peak at around the age of 90 and then decline in
the mid 90’s. Even though an individual has no way of controlling the risk factor of
aging, there are many other risk factors that fall within a persons’ ability to control.
Environmental factors including lifestyle choices have been investigated using identical
twin studies. Using twins that are discordant for AD, researchers have examined varying
environmental factors that may have played a role in the development of the disease.
One such study found that a higher level of schooling was correlated with a decreased
risk of developing AD (Raiha et al., 1998). Also, researchers from the same twin study
found that a reduced risk was associated with ambidextrousness, and an increased risk
was associated with both marriage and widowhood (Raiha et al., 1998).
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Vascular risk factors, such as hypertension, have also been shown to be associated
with AD (Skoog et al., 2003). In order for hypertension to be considered a risk factor for
AD, an individual would have experienced it during mid life, decades prior to developing
AD. Cholesterol levels have been examined as possible risk factors. Studies have shown
that individuals with higher total cholesterol levels had nearly tripled their risk in
developing AD (Wellington et al., 2004). One risk factor that can be controlled is an
individual’s diet. A diet high in vitamins C, B6, E, B12 and folate have been associated
with a lower risk of AD (Luchsinger et al., 2004). Studies have reported that diets low in
fish and cereals are associated with an increased risk for the development of AD (Grant et
al., 1999). The wide array of risk factors seen to play a role in AD, is further testament to
the complex nature of the disease in terms of both its development and progression.
Treatments
While a cure has not yet been discovered for AD, many treatments are available
that have been proven to lessen symptoms. The treatments can be broken down into two
broad categories: drug therapies and alternative treatments. Drug therapies include;
antioxidants, cholinesterase inhibitors, NMDA receptor antagonists (Memantine), antiinflammatory agents, neuropsychiatric drugs, herbal supplements, and statins. Also,
there are several drug therapies currently under clinical investigation including the antiamyloid drug Alzhemed, and estrogen replacement therapies. Alternative treatments
include psychotherapy, music therapy, exercise, and other environmentally stimulating
activities.
Alpha-tocopherol (vitamin E) has been investigated as a potential therapeutic for
AD due to its antioxidant capabilities. Vitamin E’s primary function is to defend tissues
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against oxidative damage by reducing lipid peroxidation in membranes (Conte et al.,
2004). It has been shown to successfully cross the blood brain barrier and significantly
reduce brain lipid peroxidation rates (Conte et al., 2004). In the Tg2576 mouse model for
AD, vitamin E has been shown to reduce Aβ loads (Sung et al., 2004). The increased
oxidative stress seen in AD due to deposition of Aβ and resultant neuroinflammation is
thought to play a central role in the disease. By administering a potent antioxidant such
as vitamin E, the disease progress may be retarded. Several epidemiological studies have
pointed towards the protective effects that vitamin E plays in AD, and current clinical
practice is in favor of using it as a treatment for AD (Berman et al., 2004).
Cholinesterase inhibitors have become the standard of treatment for patients with
AD (Cummings, 2004). The brain of an AD patient is marked by an extreme decrease in
cholinergic activity. A cholinesterase inhibitor works to prevent the enzyme responsible
for breaking down acetycholine, thus, increasing the amount available for neuronal
signaling. Four cholinesterase inhibitors are currently FDA approved in the treatment of
AD: tacrine, donepezil, rivastigmine, and galantamine (Cummings, 2004). Of the four,
tacrine (Cognex) is rarely used due to its potential liver toxicity (Delagarza et al., 2003).
Cinical trials have shown that treatment with cholinesterase inhibitors delays nursing
home placement and stabilizes or improves cognitive function (Delagarza et al., 2003).
The effects of cholinesterase inhibitors are however, modest. The drugs improve
cognitive function in mild dementia only and cannot prevent or slow the disease
progression (Sonkusare et al., 2005). Studies have indicated that treatment with these
drugs will delay further cognitive deterioration by about one year (Delagarza et al.,
2003).
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The FDA has also approved another drug, Memantine, for the treatment of AD.
Memantine is a partial NMDA receptor antagonist. NMDA-receptor-mediated glutamate
excitotoxicity plays a pivotal role in the neuronal death seen as a result of Aβ deposition
(Sonkusare, 2005). By blocking the function of NMDA receptors, the drug prohibits the
toxic effects of the receptors that are seen in AD. Memantine has been approved for the
treatment of moderate to severe AD, and has been found to improve cognitive, social and
physical impairments.
Antiflammatory drugs (NSAIDs) have been considered as a possible therapeutic
in AD. The inflammation seen around neuritic plaques is thought to play a role in the
subsequent neuronal damage seen surrounding the plaques (Delagarza et al., 2003). By
reducing the inflammatory response, the amount of neuronal damage could also be
limited. Large clinical trials have not yet been able to show an improvement in patients
undergoing anti-inflammatory drug therapies (Imbimbo et al., 2004). Current research
has shown the ability of selective anti-inflammatory drugs to decrease production of Aβ
(Imbimbo et al., 2004). New research is underway to develop new NSAID analogues
capable of providing both antiflammatory protection as well as anti-amyloid activity.
Patients suffering from AD often experience psychiatric and behavioral
disturbances. In order to alleviate these symptoms on both the patient and caregiver, it
has become fairly common to administer a variety of drugs used to alleviate the
individual symptoms of the patient. Anti-psychotic drugs such as risperidone are
commonly used in patients experiencing psychosis (Weiser et al., 2002). Selective
serotonin reuptake inhibitors (SSRIs) are used in patients experiencing depression. Also,
mood stabilizers and sedatives are used to help stabilize behavior in AD patients. These
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drugs are all used to manage the symptoms of AD only and do not confer any protective
or therapeutic effects to the disease itself.
Ginkgo biloba has been the most popular herbal supplement used in both the
prevention and treatment of AD. Studies have shown that AD patients treated with
ginkgo biloba have had modest improvements as compared with control groups
(Cummings, 2004). The exact function that ginkgo biloba serves is not yet clear,
however, it is thought that it confers its benefits through antioxidant and/or
vasodilatory.properties Another herbal supplement, huperzine A is also used in the
treatment of AD (Zangara et al., 2003). Huperzine A serves as a cholinesterase inhibitor,
it crosses the blood brain barrier easily, and has a prolonged biological half-life (Jiang et
al., 2003). Although it is not yet FDA approved in the United States for treatment of AD,
other countries such as China have been using this supplement for a number of years.
Cholesterol lowering drugs (statins) have been shown to have protective effects
against AD. Recent evidence suggests that cholesterol metabolism modulates Aβ
production and that drugs designed to inhibit cholesterol metabolism may be beneficial in
the treatment of AD (Wolozin et al., 2004). There have been several studies that have
reported preliminary evidence that chronic treatment with statins is linked to a
significantly decreased risk of developing AD (Wolozin et al., 2000).
There are numerous current clinical trials investigating various drug therapies
currently. A current phase III trial being conducted at the National Institutes of Health
(NIH) involves the new drug Alzehemed, a drug designed to prevent the aggregation of
Aβ and lower oxidative stress (Neurochem, Inc. 2004). Another phase III trial at the NIH
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is using a neurotrophic agent Cerebrolysin that has been found to decrease Aβ and protect
synaptic terminals in a rodent model of AD (Rockenstein et al., 2003).
In addition to the numerous pharmaceutical therapies available for AD patients
there are also several non-pharmacological treatments commonly used. Caregivers have
found that by enriching the patients environment through adding activities such as light
exercise or by allowing them to listen to music or view videotapes of family members
that their neuropsychiatric symptoms are greatly alleviated (Cummings, 2004). While
these treatments are designed to lessen the severity of symptoms during the progression
of the disease, a recent study points towards the therapeutic potential that environmental
enrichment can have. A study using a mouse model of AD found that long-term
environmental enrichment greatly improved cognitive function in animals that otherwise
are cognitively impaired (Arendash et al., 2004). This study suggests that environmental
enrichment can provide therapeutic cognitive benefits to patients with AD.

Animal Models
Transgenic Mice
Animal models have proven to be very useful in the research of many diseases
such as Parkinson’s, diabetes, and ALS. The creation of an animal model allows
researchers to test potential drug therapies as well as study in further detail the
pathologies underlying the disease. The designs and creations of animal models are
being modified as further technology and knowledge of diseases advances. While the
genes inserted or methods of gene insertion may change, the basic concept underlying the
creation of an animal model remains the same.

22

In order to create an animal model for a disease with a known genetic mutation
the gene encoding the mutation must be first identified and then cloned. Next, embryonic
stem cells are removed from the donor mother and the cloned gene of interest is inserted
into the embryonic stem cells in a random insertion through the use of a vector. The cells
that have incorporated the mutated gene are then selected and reinserted into the embryo.
The embryo is reinjected into the mother, and the resultant offspring will be a chimeric
animal. A chimeric animal contains both normal cells and cells containing the genetic
insertion or transgene. The chimeric animal will then be crossed with a wild-type mouse
to create a heterozygote transgenic animal that can be bred with another heterozygote
animal to create a homozygous transgenic animal. The resultant animal will be a
transgenic animal expressing the gene product inserted into its genome with hopes of
mimicking the human disease. An important element of designing a transgenic animal is
choosing an appropriate promoter. Promoters determine the level, tissue specificity, and
temporal pattern of the transgene being expressed (Picciotto & Wickman, 1998).
The process of creating the AD specific transgenic animals is modified slightly
from the process described above. The fertilized egg is removed from the pregnant
mother and the transgene, in cDNA form, is introduced into the single-cell mouse embryo
through pronuclear injection (Picciotto & Wickman, 1998). The transgene injected
embryo will be re-implanted into a pseudopregnant mother. The inserted DNA will
become integrated into the mouse’s genome through a random insertion event. Most
often multiple copies of the gene are integrated into the genome. The copy number can
have an affect on the transcriptional level of the gene. However, the site of integration
seems to have a larger effect on transcription. Assuming the insertion event occurred at
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the one cell stage all of the cells that compose the resultant offspring should contain the
transgene. If the insertion is done in an embryo that has already undergone multiple
rounds of cell division, then a chimeric animal will be produced.
Researchers involved in the field of AD have been successful in creating several
different mouse models of AD including the PDAPP, Psw (APP23), and the
APPsw(Tg2576) + PS1 models. All of these animal models utilize the genetic mutations
discovered in FAD in the APP and Presenilin genes. The mouse models currently used
have proven to be very beneficial to researchers in helping to elucidate further the disease
mechanisms involved in AD. There is, however, much criticism centered on the fact that
the mouse models for AD are incomplete models that do not mirror perfectly the disease
as seen in humans.
PDAPP Model
One of the first mouse models developed for AD is the PDAPP model. The
animal model was generated by a single substitution in the APP gene associated with
familial AD (P717V) being driven by a platelet-derived growth factor (PDGF)-β
promoter (Games et al, 1995). The PDAPP model expresses high levels of human
mutant APP that result in the formation of neuritic plaques, synaptic loss, astrocytosis
and microgliosis (Games et al, 1995). Plaque formation is seen between 6-9 months of
age, and is found in the hippocampus, corpus callosum and cerebral cortex (Games et al,
1995). Also, it has been reported that age-dependent changes in synaptic densities has
been seen in this animal model (Dodart et al, 2000). This animal model has failed to
exhibit any neuronal loss in the entorhinal cortex, CA1 hippocampal subfield or
cingulated cortex through 18 months of age (Irizarry et al, 1997). Synaptic transmission
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has been studied in the PDAPP model, and one study reported that there is abnormal
neurotransmission in the hippocampal circuits prior to Aβ deposition (Giacchino et al,
2000). The generation of the PDAPP mouse model has shown that the overproduction of
the mutant APP gene is sufficient to cause plaque formation with subsequent activation
of astro-glial cells that is similar to what is seen in AD (Masliah et al, 1996).
The PDAPP model also exhibits numerous behavioral impairments associated
with AD like behavior. A study reported that the model shows deficits in the radial arm
maze task (an eight-arm dry radial maze designed to test spatial discrimination) as early
as 3 months of age (Dodart et al, 1999). The cognitive deficits in spatial learning may be
due to hippocampal atrophy and modifications in synaptic density (Dodart et al, 2000).
Impairments in an object recognition task (tested by analyzing a rodents’ propensity to
explore a novel object as opposed to a familiar one in an open field) are seen at 6 months
of age in homozygous animals, and in 9-10 months of age in heterozygous animals
(Dodart et al, 1999). Another study testing PDAPP animals across a full test battery of
cognitive and sensorimotor tasks (at an early and late time point) reported that at 2
months there were no cognitive deficits in the PDAPP model (Nilsson et al, 2004).

At

the late time point (16 months), however, testing revealed an impairment in the final
block of Morris water maze acquisition and in overall radial arm water maze performance
(Nilsson et al, 2004). It is noteworthy that the mixed background of mice in the Nilsson
et al. (2004) study resulted in elimination of hippocampal atrophy present in earlier
studies (Dodart et al., 1999). Studies have also been done examining the effect of
amyloid plaque formation on behavior. One study reported that in the modified water
maze (the escape platform is moved across 5 successive locations and animals are given 8
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trials a day designed to test working memory) that both age-related and age-independent
working memory impairments are seen in the PDAPP model (Chen et al, 2000). This
study also reported that the impairments in this modified water-maze correlated with an
age-related increase in plaque burden (Chen et al, 2000). An additional more recent
study has also reported deficits in spatial learning in the circular maze task in both young
(3-5 months) and aged (20-26 months) PDAPP animals (Huitron-Resendiz et al, 2002).
The authors suggest that glucose hypometabolism, hippocampal atrophy, and age-related
increases in Aβ deposition may be the cause of the impairments seen. A study focusing
on changes in emotionality in this mouse model found abnormalities in fear (tested by
analyzing posture patterns in a fear conditioning paradigm) and exploratory activity
(tested by analyzing motor patterns in the fear conditioning paradigm) in 11 month old
females (Gerlai et al, 2002). Changes in emotionality are prominent effects of AD, and it
is therefore, important to have an animal model that incorporates not only pathological
and cognitive changes but also emotional changes that mimic AD.
Psw(APP23) & APPsw Models
The “Swedish Mutation” was discovered in the gene encoding the APP protein in
a Swedish family with a familial form of AD. The mutation has been used in the
development of two animal models: the Psw (APP23) and the APPsw (Tg2576). Both of
these animal models contain the same transgene with a double mutation (K670N-M671L)
found in the 695 amino acid long human APP gene (Mullan et al, 1995). These two AD
animal models differ in the promoters used to drive expression of the mutant APP and the
insertion sites of the transgene (both insertions are random events). These differences
result in two animal models showing unique pathologies.
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The APPsw (Tg2576) mouse model for AD contains the 695 amino acid long
human APP gene encoding the double mutation found in a Swedish form of familial AD
(K670N-M671L) driven by a hamster prion protein promoter (Irizarry et al, 1997). The
Tg2576 animal model exhibits soluble Aβ formation at 6 months of age and plaque
formation by 11-13 months of age accompanied by neuritic dystrophy and activated
astrocytes and microglia (Irizarry et al, 1997). Plaques are found predominately in the
cortical and limbic regions of the brain. This model expresses the mutant APP only in
neurons, presumably due to the actions of the prion promoter (Hsiao et al, 1995). Glialmediated inflammatory response has been studied in detail in the Tg2576 model. It has
been found that the inflammatory cytokine interleukin-1β and the tumor necrosis factor α
are localized to Aβ plaques (Benzing et al, 1999). Also this animal model has been
shown to express increased glial fibrillary acidic protein, a protein found to be increased
in the AD brain (Lim et al, 2000). This model does not have any neuronal death in the
CA1 region of the hippocampus, a region that undergoes profound loss of neurons in
human AD (West, 1994). The behavioral deficits seen in this animal model maybe
attributed to impairments in synaptic plasticity (Chapman et al, 1999).
Sensorimotor analysis of the Tg2576 model has yielded conflicting results. One
study reported deficiencies in the balance beam and string tests at 3-, 14-, and 19-month
old animals (King & Arendash, 2002). Another study also found impairments in balance
beam at 5 and 6.5 months of age (Arendash et al, 2004). In contradiction to these
findings, a study by Lalonde et al (2003) reported that between 15-20 months of age
(average age 17 months), the Tg2576 model did not display any deficits on the balance
beam and rotorod test. The discrepancy may be due to differences in equipment used to
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test the animals or, less likely; it may be due to differences in the strain background of the
mice used. The Tg2576 model has also been shown to exhibit increased activity in the
open field test at 17 months of age (Lalonde et al, 2003). Similar findings regarding
activity level have been reported. A study done reported that at 3 months of age there
was a significant increase in activity in the open field task, and overall increased activity
through 19 months of age (King & Arendash, 2002). In disagreement to these findings of
increased activity a study done on 5 month old mice reported no differences in
activity/exploratory activity (Arendash et al, 2004). Changes in anxiety have also been
reported. A study done using Tg2576 animals at 17 months of age reported finding
reduced anxiety in the elevated plus maze (Lalonde et al, 2003). A study done in younger
mice, 5 months of age, reported no differences in anxiety in the elevated plus maze
(Arendash et al, 2004). The seeming discrepancies found in the Tg2576 model may be
attributed to a number of variables including differences in background strain, alterations
in procedures used during testing, and use of animals at various ages.
There have also been conflicting reports regarding the cognitive abilities of the
Tg2576 model. The Y-maze task for spontaneous alternation has been utilized by several
researchers in characterizing the Tg2576 model. One study reported that at 3 and 19
months of age Tg2576 mice had significantly reduced spontaneous alternations; however
at 9 and 14 months of age there was a modest impairment only (King & Arendash, 2002).
The authors suggest that the Y-maze task may be relatively insensitive to cognitive
impairment associated with the transgene, possibly accounting for the differences in ages
at which researchers report finding impairments. Another study tested spontaneous
alternation at 3 and 10 months of age and reported that only at 10 months of age was
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there significantly less spontaneous alternations in transgenics compared to nontransgenic controls (Hsiao et al, 1996). A study done on 17 month old Tg2576 mice
reported impaired spontaneous alternation (Lalonde et al, 2003). In agreement with these
results another study tested spontaneous alternation at 5 and 8.5 months and reported that
overall there was a significant impairment (Arendash et al, 2004). Regardless of the
exact time point in which impairments are seen in the Y-maze, impairments are
consistently found in the performance of the Tg2576 mouse model for this test of
cognitive function.
The circular platform (a spatial reference memory task) is also used to test
cognitive function in rodent models. A study done in 7 month old Tg2576 mice revealed
an impairment in circular platform “reversal learning” (modified methodology in which
animals must relearn a new escape location) (Pompl et al, 1999). A study done on 3, 9,
14, and 19 month old Tg2576 mice found no significant decreases in performance in the
standard circular platform task (7 days of testing omitting the “reversal learning” phase)
(Arendash, 2002). A more recent study using the standard protocol for circular platform
testing also reported no impairment at 6 months of age (Arendash et al, 2004).
The Morris water maze is another task that is commonly used by researchers and
is designed to test reference/spatial learning and memory. A study was done on 2-, 6-, 910, and 12-15 month Tg2576 mice investigating performance in the Morris water maze
(Hsiao et al, 1996). The 12-15 month old mice were tested in a follow up study that
retested a subset of the original 2 and 6 month old mice. The study revealed that at the 2
and 6 month time points there was not a significant difference between the transgenic and
non-transgenic matched controls in the Morris water maze task. At the 9- to 10 month
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age, the escape latency of transgenic mice during acquisitional testing was significantly
increased; during the probe trial, the transgenic animals had a significantly reduced
number of center crossings (Hsiao et al, 1996). The 12-15 month old mice showed
impaired latencies after the 5th trial block and on probe trials. Another study was done
using the Morris water maze on 3, 9, 14 and 19 month old Tg2576 mice. Compared to
non-transgenic controls, Tg2576 mice were unimpaired collectively and at separate time
points in both the learning and memory retention phase of testing (King & Arendash,
2002). A recent study was done on 5.5 month old Tg2576 mice and found impairment in
escape latency (time taken to find the submerged escape platform) across all 9 days of
testing, the earliest time point at which impairment has been observed (Arendash et al,
2004). This study also reported an impairment in the memory retention trial (final probe
trial day 10) and an overall impairment over all three probe trials. The apparent
inconsistent Morris water maze results in the later two studies from the same laboratory
(King & Arendash, 2002; Arendash et al., 2004) may be due to differences in the strain
background. The colony’s crossbreeding over several years has apparently resulted in
both their Tg2576 and APP/PS1 lines becoming behaviorally more sensitive to mutant
APP expression and/or the process of Aβ deposition at an earlier age.
The Tg2576 model has also been evaluated in the radial arm water maze
(RAWM), an excellent working memory task showing a high degree of sensitivity to Aβ
deposition in numerous AD transgenic lines (Arendash et al, 2001). At 6.5-7 months
Tg2576 mice have been reported to show working memory impairments as assessed
through Trials 4 and 5 of the RAWM (Arendash et al, 2004). This study also revealed
especially prominent impairments in trial 5 of the RAWM, designed to mimic
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“registration-recall” tesing of AD patients, providing added evidence for the working
memory impairment seen. It is widely reported that cognitive impairments in the Tg2576
model precedes the appearance of Aβ plaque formation at around 9-11 months,
suggesting that the soluble form may be causing the early phase of cognitive impairment
(King et al, 1999).
Also preceding plaque formation is evidence of increased oxidative stress in the
form of lipid peroxidation. A study done examining the urine, plasma, and brain tissues
for the lipid peroxidation by product 8,12-iso-iPF2α-VI, found that at 8 months of age all
of the samples showed increased lipid peroxidation (Pratico et al, 2001). Another study
examining the oxidative stress markers NHE and HO-1 also found that the Tg2576 model
exhibits oxidative damage associated with Aβ accumulation (Smith et al, 1998).
The primary pathological difference between the APP23 and Tg2576 mouse
model is found in the vasculature. The APP23 model exhibits deposition of Aβ in the
cerebral vasculature (CAA) that is remarkably similar to that observed in human AD
(Calhoun et al, 1999). The CAA found in the APP23 model is associated with local
neuronal death, dysfunctional synapses, activation of microglia and microhemorrhage
(Calhoun et al, 1999). The APP23 model can also serve as a mouse model of cerebral
amyloid angiopathy. The accumulation of Aβ in the arterioles and capillaries leads to
the death of vascular smooth muscle cells, aneurismal vasodilatation, and a weakening of
the vessel wall that can lead to rupture and severe hemorrhage (Winkler et al, 2001).
CAA is one of the prominent features of AD thus, making the APP23 animal model a
valuable tool in the study of AD (Mueggler et al, 2004).
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The APP23 mouse model displays impaired spatial learning abilities at 2 years of
age in the Morris water maze, and hyperactivity assessed through the open field task
(Dumont et al, 2004). Learning and memory deficits in the APP23 model, as examined in
the Morris water maze, have been reported as early as 3-months of age (Van Dam et al,
2003). An additional study found an impairment in latency and swim distance beginning
at 3 months of age and persisting through 18 months (Kelly et al, 2003). A study looking
at 16 month old female APP23 mice found an impairment of spatial learning in the
Morris water maze (Lalonde et al, 2002). Studies have also reported disturbed activity
patterns similar to the disturbances in circadiam rhythms seen in AD patients (Van Dam
et al, 2003).
APPsw + PS1 Models
Given the knowledge that mutations in the presenilin 1 (PS1) and presenilin 2
(PS2) gene results in the familial form of AD, the creation of an animal model expressing
these mutations was created. As discussed earlier the missense mutations in PS1 and
PS2 alters APP processing resulting in the formation of the toxic Aβ 1-42 (Borchelt et al,
1997). Single transgenic animals expressing the PS1 mutant transgene are not seen to
produce significant amounts of Aβ pathology, however, there is a drastic increase in the
ratio of Aβ1-42/ Aβ1-40 levels (Duff et al, 1996). By crossing the PS1 (M146L) animal
model with the Tg2576 mouse, a double transgenic animal (APP/PS1) is produced that
exhibits earlier and more pronounced AD like pathology (Borchelt et al, 1997; Holcomb
et al, 1998).
Aβ deposition in the APP/PS1 is seen as early as 12 weeks in the cortex and
hippocampus, far earlier than what is seen in the Tg2576 model (Holcomb et al, 1998).
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By 12 months of age there is a 20 fold increase in Aβ deposition in the frontal cortex and
a 40 fold increase in Aβ deposition in the CA1 region of the hippocampus as compared
with the Tg2576 model (Takeuchi et al, 2000). The diffuse Aβ plaque burden (detected
through immunostaining with 4G8) peaks at around 1 year of age, however, the fibrillar
form of Aβ (detected through thioflavin s staining) increases through 2.5 years of age, the
latest time point tested (Matsuoka et al, 2001). The Aβ plaque formation activates
astrocytes and microglia. The numbers of activated astrocytes and microglia increase in
parallel with Aβ plaque loads (Matsuoko et al, 2001). This robust Aβ deposition
alongside activated astrocytes and microglia in the APP/PS1 model has resulted in the
model becoming very popular currently amongst researchers. Recently, it has been
reported that the APP/PS1 model exhibits abnormal LTP at 3 months of age, and
impairments in basal synaptic transmission (BST) at 6 months of age (Trinchese et al,
2004). Both LTP and BST are underlying processes that occur during memory
consolidation and abnormalities in their functioning result in memory deficits. Another
study also looking at LTP and synapse function used microarray and quantitative RTPCR to profile synaptic plasticity genes in the APP/PS1 model. These researchers found
reduced mRNA expression of several genes necessary for LTP (Zif268, NR2B, GluR1,
etc.) (Dickey et al, 2003). Neuronal morphology in the APP/PS1 model has also been
studied using labeling techniques. It is reported that at 11 months of age, the APP/PS1
model displayed swollen bulbous dystrophic neurites alongside significantly reduced
spine numbers and reduced total spine area (Moolman et al, 2004). A decrease in the
density of cholinergic synapses in the frontal cortex and a decrease in the size of
cholinergic synapses in the frontal cortex and hippocampus has been reported at 8 months
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of age (Wong et al, 1999). While the exact cause of the synaptic dysfunction is not yet
known, it is quite evident that the APP/PS1 model exhibits dysfunctional synaptic
function as evidenced by multiple studies. In aged (22 months) APP/PS1 mice,
researchers have found a reduced level of glucose utilization in the hippocampus
accompanied by a 35.8% dropout of neurons in the CA1 region (Sadowski et al, 2004).
The report of neuronal dropout is novel. Prior to this study no findings of neuronal death
in the APP/PS1 model had been reported (Takeuchi et al, 2000).
Behavioral testing of the APP/PS1 model has been done including testing in
sensorimotor, anxiety and cognitive tasks. Sensorimotor testing has revealed
impairments in this mouse model. An impairment in sensorimotor function assessed by
the balance beam task has been found to emerge as early as 5 months of age and persist
through 16 months of age (Arendash et al, 2001). In contrast to this study a study
reported that no sensorimotor function impairment was found in 4.5-6 and 15-16.5 month
old animals in the balance beam task (Jensen et al, 2005). The string agility test (a task
measuring sensorimotor ability) revealed no differences at 5-7 months of age, and
impairments were found at 15-17 months of age as compared to non-transgenic controls
(Arendash et al, 2001).
Anxiety and activity testing have also been performed on this animal model. The
Y-maze alternation task is also used to determine an activity index through measuring the
total number of arm entries. In this task 3-3.5 month old APP/PS1 mice had increased
activity as compared with singly transgenic or non-transgenic littermates (Holcomb et al,
1998). Another study found similar results reporting that in 5-7 and 15-17 month old
APP/PS1 mice there was a significant increase in arm entries (Arendash et al, 2001).
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Open field testing (a task measuring activity and exploratory levels), has revealed
increased activity levels at 15-17 months of age (Arendash et al, 2001). A study done on
8 and 22 month old APP/PS1 mice showed no significant changes in activity levels tested
in an open-field task (Sadowski et al, 2004). Open field testing has been shown to reveal
decreased activity (measured through horizontal locomotor movements) in 7 month old
APP/PS1 mice (Liu et al, 2002). However, in contrast, a study has reported that at 4.5-6
months of age APP/PS1 mice had increased open field activity (Jensen et al, 2005).
Anxiety testing on the elevated plus maze has revealed increased anxiety in animals 1516.5 months of age (Jensen et al, 2005). Overall, the majority of studies (Holcomb et al.,
1998; Arendash et al., 2001; Jensen et al., 2005) report increased activity in the APP/PS1
model. This increase in activity begins to emerge as early as 3 months of age and is still
apparent at 15-17 months of age. The studies that reported either no significant changes
in activity (Sadowski et al., 2004) or decreases in activity (Liu et al., 2002) both used
photoactometers to assess movement. The use of a photoactometer is a more sensitive
technique as it utilizes interruptions in photobeams capable of sensing horizontal and
vertical motion to assess movement; whereas the open field testing employed in the other
studies mentioned above utilized the number of line crossings (horizontal movement) in
the open field as the only measure of activity. Thus, the conflicting results may be due to
differences in equipment used.
Cognitive testing including tasks such as the Y-maze alternation task,
Morris water maze, and radial arm water maze (RAWM) have shown conflicting results.
The Y-maze task of general memory function, revealed an impairment in spontaneous
alternations in APP/PS1 mice at 3-3.5 months (Holcomb et al, 1998). However, another
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study has reported no differences in Y-maze performance at 5-7 months of age (Arendash
et al, 2001). A recent study reported finding no differences in spontaneous alternation in
the Y-maze task at both 4.5-6 months and at 15-16.5 months (Jensen et al., 2005). As
mentioned prior the incongruity of findings in the Y-maze task for spontaneous
alternations may be due to the non-specificity of the task to the impairments conferred by
the APP/PS1 genes.
Spatial memory and learning assessed in the Morris water maze revealed no
differences in escape latency, time spent in goal arm, or number of platform crossings in
animals at 9 months of age (Holcomb et al, 1999). However, a longitudinal study testing
at 4.5-6 months and again at 15-16.5 months found a significant impairment in escape
latencies at both time points (Jensen et al, 2005). The Jensen et al., 2005 study also
reported that in the probe trial at 4.5-6 months there was s significant reduction in
annulus crossings as compared with the non-transgenic group; and at 15-16.5 months
there was no difference in performance. Working memory has been tested in the radial
arm water maze task in the APP/PS1 model at several different ages. A longitudinal
study using 5-7 month old APP/PS1 found no differences in the RAWM and at 15-17
months reported that the APP/PS1 animals made significantly more errors during trial 5,
the memory retention trial in the RAWM (Arendash et al., 2001). An impairment in
working memory during radial arm water maze (RAWM) testing has been found in the
APP/PS1 model at 16 months of age, as measured by the number of errors animals made
during trial 5 of the task (Austin et al., 2003). Two recent studies have reported
impairments in working memory at a much earlier age. A study done on 6-8 month old
APP/PS1 mice reported finding significantly more working memory errors in the

36

APP/PS1 animals vs. the non-transgenic controls in the RAWM (Trinchese et al, 2004).
An even more recent study reported that APP/PS1 animals at 4.5-6 months of age made
significantly more working memory errors in the RAWM task, revealing cognitive
deficits at a much earlier age than previously reported (Jensen et al, 2005). Interestingly,
the same transgenic colony was utilized in both Arendash et al., (2001) and Jensen et al.
(2005) for RAWM testing. The much earlier impairments in working memory found by
Jensen et al., 2005 may be attributable to the fact that the colony utilized during the test
battery had been cross-breed over several generations and the resultant transgenic mice
may have become more behaviorally sensitive to mutant APP expression and/or the
process of Aβ deposition.
Using the most recent and thorough behavioral evaluation of this model by Jensen
et al (2005), an overview of the APP/PS1 model can be formed. The APP/PS1 model
was reported by Jensen et al, (2005) to be cognitively impaired at 4.5-6 months of age in
the RAWM task (assessed through number of errors, impairment seen overall and in last
block), showing impairments in working memory. From this data it is reasonable to
assume that any treatment/study that aimed at utilizing animals that are trending towards
impairment should begin around 3 months of age. Jensen et al., (2005) reported that at
4.5-6 months of age this model had a significant impairment in Morris water maze
acquisition and retention. These findings show an impairment in working and spatial
reference memory in the APP/PS1 model at this early time point. Jensen et al, (2005)
reported that at the late 15-16.5 month time point an additional cognitive impairment was
found in the platform recognition task. Thus, in the APP/PS1 model, one could expect to
find a significant cognitive impairment in working, reference and long-term memory to
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emerge at 4.5-6 months of age (tested by either the Morris water maze or RAWM) and
expect the impairment to persist through 15-16.5 months.
Transgenic animal models have provided researchers with a powerful tool in the
study of AD. Animal models are, however, an incomplete model of AD due to their
lacking of the complete set of pathologies seen in AD. All of the mutant transgenic APP
lines (PDAPP, APP23, Tg2576, APP/PS1) completely lack the formation of NFT’s
(Loeffler, 2004). As discussed prior, NFT’s are one of the pathological hallmarks of AD.
It is, therefore, desirable that an animal model would form NFT’s. The APP mouse
model also differs from AD in regards to their immune and inflammatory response. The
APP transgenic mouse displays only weakly activated microglia expressing low levels of
complement factors that were gathered only around the periphery of plaques (Schwab,
2004). This is in stark comparison with the human response which involves microglia
found within the core of the plaques that are highly activated and express high levels of
complement factors (Schwab, 2004). The reason for this diminished immune and
inflammatory response in unknown, although it has been hypothesized that it is due to
low recognition of mouse complement factors to human Aβ (Webster, 1997). The
plaques themselves are more fibrillar in state, with fibrils radiating out from a dense core,
whereas human AD exhibits plaques in a more homogenous state (Schwab, 2004). The
Aβ deposits in the APP23 model are soluble in SDS-containing buffer, however, human
AD deposits are insoluble (Schwab, 2004). These differences may be due to posttranslational modification differences in the mouse model. The more fibrillar and toxic
nature of the animal model plaques has not been definitively shown to result in increased
neuronal death. One study reported finding neuronal loss in a limited region around Aβ
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plaques in the Tg2576 model (Tomidokoro, 2001) A study using 16 month old Tg2576
mice found no neuronal loss (Stein, 2002). The debate is centered on whether there is
“limited” neuronal loss; however, it is apparent that the animal model does not display
the profound neuronal losses seen in AD. The mutant APP transgenic animal model is
therefore only a limited model for AD. The lack of a robust immune and inflammatory
response may suggest that this animal model be limited to studies involving the
prevention of Aβ accumulation (Schwab, 2004).
There are also limitations in the mouse model regarding behavior. Ideally, an
animal model for a disease mimics that found in humans, but due to the highly
psychologically-based nature of AD it is impossible to create a complete mouse model.
One of the first striking deficits in using a mouse model is the inability to test verbal
skills. Also, it is very difficult to test an animal model for any of the psychoses
experiences by AD patients such as hallucinations, depression, and apathy. While there
is extensive memory testing in animal models, it is impossible to assess semantic
memory. Most behavioral studies use mazes with varying escapes and measures the
ability of an animal to learn the escape, thus giving the researcher insight into the
animals’ short and long-term spatial memory skills. Semantic memory, ability to
recognize people, places, etc. is difficult to measure in an animal model. Often an AD
patient will forget a loved ones’ face or be unable to recognize voices of their loved ones.
This type of deficit in semantic memory is readily apparent in AD. However, animal
testing is limited to testing only object recognition in memory tasks or identification of an
escape platform. Nonetheless, animal models have proven to be highly useful in AD
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research. It is however, important to understand the limitations that are faced when using
animal models in AD research.

Hyperoxia
Behavior
It is estimated that the human brain consumes approximately 20-30% of total
energy usage for the entire body and is considered to be the most metabolically active
organ (Roland, 1993). Oxygen is regularly consumed by brain cells during normal
cellular respiration (Benton et al, 1996). Given this knowledge it is reasonable to assume
that varying oxygen saturation levels (hyperoxia or hypoxia) would affect cognitive
functioning as well as other metabolic parameters. Researchers have been investigating
the effects of administering hyperoxia (oxygen level above 20.9 %) treatments in humans
for several years.
A recent study done by Andersson et al (2002) found no differences in cognitive
performance after subjects (48 participants with a mean age of 21.1 ±6.49 years) inhaled
100% oxygen for 1 minute prior to the start of testing. The cognitive testing given
during this study was designed to assess working memory, prospective memory, attention
and long-term memory. This study also examined physical changes that occurred during
the treatment. They found that individuals who underwent the hyperoxia treatment had
significantly higher oxygen blood saturation, lasting for 1 minute post treatment
(Andersson et al, 2002). Heart rate was not affected by the treatment. This study is in
contradiction to several others (Moss et al, 1998; Scholey et al, 1998;1999), who have
found significant cognitive improvements following treatment with hyperoxia.
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An older study done by Moss et al (1998) reported a significant improvement in
immediate and delayed word recall in test subjects (20 participants aged 21-48 years)
exposed to 100% oxygen for a duration of 1 minute or 3 minutes prior to the start of
testing. This study used 4 different schedules of hyperoxia treatment; 30 seconds, 1
minute, 3 minutes, and constant oxygen administration throughout the test session. The
constant oxygen schedule did not show improvements in the cognitive tasks. The
researchers speculated that there is a point in which an enhancing factor becomes
deleterious. Working memory did not show any enhancement in any of the hyperoxia
treatment groups. The researchers suggest that the placement of the working memory
task at the end of the test battery may account for their finding. Overall, the authors
reported that transient administration (1 and 3 minute exoposures) of 100% oxygen
improved attention, vigilance and long term memory. They hypothesized that the
transient increase in oxygen saturation may result in a global upgrade in metabolites that
enhance cognition.
Two studies done by Scholey et al (1998 & 1999) also reported cognitive
improvements after exposure to hyperoxia. The study done in 1998 (20 participants with
a mean age of 21 years) found enhanced word recall in test subjects exposed to 100%
oxygen 5 minutes prior to, immediately before or immediately after word presentation.
This study used multiple schedules of treatment given 5 or 10 minutes prior to word
presentation, or 5 or 10 minutes after word presentation. The study showed that subjects
given oxygen 10 minutes before or 10 minutes after word presentation did not show any
improvements. The cognitive testing was limited to word recall. The researchers
examined oxygen saturation and reported that the effects of the hyperoxia treatment on
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saturation were apparent immediately before, during, or after word presentation where
word recall was enhanced. This supports their hypothesis that the additional blood
oxygen resulting from the hyperoxia treatments is utilized through the neural mechanisms
responsible for memory formation. The study done in 1999 by Sholey et al. had similar
findings. Subjects (34 participants with a mean age of 21 years) were exposed to
hyperoxia for 1 minute and then tested for reaction time and word recall. The subjects
who received the hyperoxia treatments recalled more words and had faster reaction times.
Alongside cognitive testing, oxygen saturation was also measured. A significant increase
in blood oxygen saturation was seen in the subjects exposed to the hyperoxia that
persisted from the gas administration phase through the word presentation phase of the
experiment. This finding, in conjunction with the improvements seen in word recall, led
the authors to conclude that the elevated blood oxygen is utilized by task-sensitive neural
substrates during period of cognitive processing. In all of the studies listed above it is
important to note that they utilized an acute administration of oxygen. The effects of
longer-term oxygen administration (for a period of several hours rather than minutes) on
cognitive performance could, therefore, have drastically different results. It is also
important to note that hyperoxia has not been found to have deleterious effects on the
cognitive function of healthy individuals. A study done by Prior & Chander (1982)
found that hyperoxia exposure (12 hour treatment) post-surgery to elderly patients did not
show any deleterious cognitive effects. It is important to note that cognitive testing was
performed shortly after hyperoxia exposure (not months thereafter).
There has only been limited research done on the behavioral effects of hyperoxia
in rodent models. A study done by Fukui et al (2001) examined learning and memory in
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a rat model for oxidative stress. The study involved three different ages of rats; 3
months, 15 months, and 25 months. An additional group of animals were fed a vitamin-E
deficient diet for 9 weeks prior to testing. The animals were given time to learn the
Morris water-maze task prior to exposure to hyperoxia. After the animals had adequately
learned the task they were exposed to 100% oxygen for a lengthy 48 hours prior to the
memory retention phase of Morris water-maze testing. Performing retention trials daily
for up to 14 days after hyperoxia exposure, they claim that not all of the animals could
relearn the task suggesting that the damage done during the treatment was long lasting.
The methods used to conclude that the animals could not relearn the task were somewhat
confusing. By performing repeated probe trials the researchers were actually assessing
“memory-extinction” (long-term memory) rather than the animals’ ability to relearn.
Also the study lacked a full explanation of the statistical measures used in their
behavioral analysis. However incomplete this study may be, these findings do point
towards the toxic nature of long-term exposure to hyperoxia in a rodent model
Pathological and Physiological Effects of Hyperoxia
Hyperoxia is commonly used in hospitals to treat asthma, chronic obstructive
pulmonary disease (COPD), premature babies, patients with severe head injury, etc
(Pagano & Barazzone-Argiroffo 2003). The use of hyperoxia in severe head injury has
been controversial. A study done by Tolias, et al (2004) revealed benefits of using
hyperoxia in patients with head injuries. Using patients with severe head injuries
exposed to 100% oxygen for 24 hours the researchers examined five cerebral metabolic
markers. They found increased glucose levels, decreased glutamate and lactate levels,
and reduced intracranial pressure in the group exposed to hyperoxia. Another study done
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by Magnoni, et al (2003) also found decreases in lactate. However, they reported no
differences in glucose and glutamate levels. A decrease in lactate has also been reported
by Schaffranietz, et al (2000) in patients exposed to hyperoxia. These differences may be
attributed to the fact that the patients used in the Magnoni, et al (2003) study only
received 3 hours of hyperoxia. Of course, treatments with hyperoxia also increase a
patients’ oxygen saturation making it beneficial to anyone suffering from a disease in
which low blood oxygen saturation is a symptom (Kergoat & Faucher, 1999).
While hyperoxia does have some limited benefits there is growing evidence that
the treatment has many harmful side effects resulting in permanent damage. One of the
most profound and widely documented effects of hyperoxia is found in the vasculature.
Hyperoxia is a potent cerebral vasoconstrictor (Ouattara et al, 2004). A study done in
humans using MRI to analyze the influence of hyperoxia on cerebral blood flow reported
that during hyperoxia, patients had diminished regional cerebral blood flow in all regions
except in the parietal and left frontal gray matter (Kolbitsch et al, 2002). The exact
mechanisms underlying oxygen induced vasoconstriction are still under investigation.
The enzyme super-oxide dismutase (SOD) alongside the signaling molecule nitric oxide
(NO) is thought to regulate vasoreactivity. SOD catalyzes the dismutation of superoxide
radical (O2-) to hydrogen peroxide. Approximately 5% of inspired oxygen is converted to
the dangerous superoxide radical (Fridovich, 1983). The SOD class of enzymes plays an
important role in antioxidant defense mechanisms. SOD enzymes are implicated in
diseases involving oxidative stress such as AD. NO is a diffusible gas that is found in
neurons, macrophages and epithelial tissues. In epithelial tissue it functions to relax
smooth muscle in the arteriole walls resulting in vasodilation. A study by Johnson (2001)
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has shown that O2- reacts with NO to form the toxic peroxynitrite (ONOO-).
Peroxynitrite is a potent oxidant that can react with DNA, proteins, and lipids leading to
cellular damage. Johnson (2001) also suggested that increased levels of brain ONOOcan further worsen the damage caused by the overactive microglia, further advancing the
progression of AD. A study done by Demchenko, et al (2002) investigated the role of
SOD in oxygen-induced cerebral vasoconstriction. The study revealed that SOD
promotes cerebral vasodilation by scavenging free O2- in a normal state system. During
hyperoxia, they found that the effects of brain NO were decreased due to the increased
O2- production, resulting in vasoconstriction. Thus, SOD works by regulating the
availability of O2- to act as a vasoconstrictor by degrading the radical, allowing for NO
induced vasodilation. In a study done by Park, et al (2005) the effects of NADPH
oxidase-derived ROS and Aβ were investigated in regards to cerebrovascular
dysfunction. The authors also came to the conclusion that the effects of ROS mediating
cerebrovascular dysfunction involve reduced bioavailability of the vasodilator nitric
oxide. A study done by Sjoberg, et al (1999) quantified the vasoconstriction seen in the
CNS during hyperoxia in a pig model for hyperoxaemia (condition in which the arterial
partial pressure of oxygen exceeds 80 mm Hg). They reported that after 25 minutes of
administration of 70% oxygen they found an 11% reduction in capillary blood flow,
alongside a significant increase in cerebrocortical tissue oxygenation. This decrease of
blood flow may be a protective mechanism. By reducing the brains exposure to the toxic
high levels of oxygen that are generated during hyperoxia, the brain may be reducing the
possible damage incurred.
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As mentioned prior, the AD brain contains elevated levels of Aβ. The increased
brain Aβ levels seen in the APPsw mouse model may play a contributory role towards
their increased susceptibility to brain ischemic injury (Xu et al, 1998). Alongside these
findings it has also been reported in a study by Iadelcola, et al. (1999) that APP717
transgenic mice have an alteration in cerebrovascular regulation; specifically, there is a
reduced vasodilatory response to acetycholine and an enhanced response to
vasoconstrictors. This suggests that the impairment seen in cerebrovascular
responsiveness results in vasculature more prone to vasoconstriction. Several additional
studies have been done further investigating the effects of Aβ on endothelial dysfunction.
An in vitro study was done by Thomas, et al (1997) revealed that Aβ increased cerebral
vasoconstriction, and decreased vasodilation. The authors also reported that the Aβ
induced endothelial cell damage, apparently caused by reactive oxygen radicals produced
by Aβ. Also, the authors suggest that the vascular damage done by Aβ may be an early
event in AD. Another in vitro study done by Crawford, et al (1998) further supports the
finding that Aβ enhances vasoconstriction in rat aortae. Specifically, the authors looked
at the effects of Aβ1-40 & Aβ1-42 on vasoconstriction. They found that Aβ1-40 had a more
profound vasoconstrictive effect than Aβ1-42 . Interestingly, the authors also reported that
the endothelium is not required for vasoactivity. Aβ-induced vasoactivity is seen
immediately after exposure to solubilized Aβ, and the lack of requirement of the
endothelium suggest that the imabalance between NO and O2- works alongside Aβ to
further increase vasoconstriction. These authors also suggested that chronic
vasoconstriction would result in subclinical ischemia that would in turn stimulate
increased Aβ formation around the vasculature. In vivo studies have also been done
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providing additional evidence that Aβ serves as a vasoconstrictor. A study done by
Arendash, et al (1999) revealed that spontaneously hypotensive rats infused with Aβ1-40
experienced substantial increases in mean arterial blood pressure (MAP). Hypertension
has been recognized as a risk factor for AD (Kokmen, et al, 1991), and longitudinal
studies have shown that elevated blood pressure is associated with development of the
disease 10-15 years later (Skoog, et al, 1996). The authors suggest that the disease
process itself may induce the onset of hypertension during the 10-15 years before clinical
onset. Also the author suggests that the Aβ-induced vasoconstriction demonstrated in the
rat model may play a contributory role to the AD process in humans. Another study
done by Suo, et al. (1998) reported that rats infused with Aβ1-40 had decreased cerebral
blood flow and increased cerebro-vascular resistance. This study found that Aβ
specifically affected cerebral vasculature, suggesting that the cerebral hypoperfusion that
is observed in early AD may be the result of Aβ induced vasoconstriction. Consistent
with the findings in murine models, human studies using PET have also revealed that in
the AD brain there is reduced vascular activity to vasodilatory stimuli (Mentis et al, 1996;
Warkentin & Passant, 1997).
The pathological effects of hyperoxia in rodent models have been much more
extensively studied. A study done by Urano, et al (1997) using a rat model investigated
the morphological changes through electron microscopy in the brain associated with
exposure to 100% oxygen for 48 hours followed by immediate sacrifice. They found
swollen astrocytes around vessels, deformed nerve cell nuclei, swollen mitochondria, and
abnormal accumulation of synaptic vesicles in swollen nerve terminals. Also, they
reported changes in the plasma membrane including decreased membrane fluidity,
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increases in membrane permeability to sucrose, and an increased
cholesterol/phospholipids ratio of the membrane. The authors suggest that the increased
amount of free radicals generated may damage nerve terminals and peroxidize the plasma
membrane.
Several studies have been done examining the cellular and biochemical effects
that hyperoxia has on the brain. The effects of hyperoxia on inducible nitric oxide
synthase (iNOS) expression has been studied in rat pups by Hoehn, et al (2003). Seven
day old rat pups were exposed to >80% oxygen for 24 hours, immediately sacrificed, and
then the amount and distribution of iNOS was examined. Biologically, iNOS is an
enzyme responsible for synthesizing NO (a vasodilator). The study revealed that
animals exposed to hyperoxia had increased total brain iNOS levels. The increased
iNOS lead to the formation of peroxynitrite (NO- + O2- → ONOO-), a toxic molecule that
can cause oxidative cellular damage. The researchers concluded that the increase in
iNOS and resultant increase in peroxynitrite may lead to subsequent damage to brain
structures. Another study done by Mamdouha, et al (1986) also looked into the effects
of hyperoxia on brain structures and found neuronal necrosis. The study utilized a series
of different schedules of alternating hypoxia/hyperoxia treatments (100% O2 for 3 hours)
in both young and adult rats that were immediately sacrificed following treatment. The
study revealed extensive neuronal karyorrhexis in the subiculum, cingulated cortex,
thalamus, and reticular formation in newborn rats exposed to hyperoxia. The more
mature and the adult rats did not develop any neuronal karyorrhexis demonstrating their
ability to cope with the treatment better. The researchers hypothesized that the selective
vulernability of the immature brain was due to lack of full development of the antioxidant
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defense mechanisms seen in the adult animal. Also, the researchers hypothesized that
the neuronal necrosis seen in the newborn rats may be the result of lipid peroxidation of
the cell membranes due to the antioxidant defense mechanisms becoming overwhelmed.
An additional study done by Taglialatela, et al (1998) was done examining effects of
antioxidants in rats exposed to hyperoxia. The study used two groups of newborn rats;
one control group and one group given Buthionine sulfoximine (BSO) a glutathione
synthesis inhibitor. Glutathione is a powerful antioxidant and can provide protection for
the mitochondria against oxygen radicals. The animals were exposed to 95% oxygen for
5 days, sacrificed immediately, and measured for nerve growth factor protein (NGF),
glutathione, and the extent of apoptosis. The study revealed that hyperoxia decreased the
amount of NGF protein, and that the animals treated with both the BSO and hyperoxia
had a substantial increase in brain apoptosis. The authors suggest that the oxidative stress
of hyperoxia in conjunction with limited glutathione resulted in neuronal damage. Thus,
several studies have revealed that in a brain that is limited in its antioxidant capabilities
hyperoxia can induce neuronal damage. It is important to note that the above studies
(Hoehn et al, 2003; Mamdouha et al, 1986; Taglialatela et al, 1998) sacrificed the animals
immediately following the hyperoxia treatment limiting the scope of effects to only the
immediate and short-term effects.
Numerous studies examining the effects of hyperoxia in lung tissue have also
been conducted. Hyperoxia has been widely documented to cause extensive alveolar cell
death through mechanisms still under debate (Pagano & Barazzone-Argiroffo, 2003). A
study done by Buccellato, et al (2004) examined the role of reactive oxygen species
(ROS) such as O2- in the induction of cell death. The researchers exposed rat epithelial
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cells to hyperoxia and found that the treatment resulted in activation of Bax in the
mitochondrial membrane with subsequent cytochrome c release and cell death. Bax is a
pro-apoptotic protein that is involved in regulating programmed cell death (De Smet et al,
2004). The researchers hypothesized that Bax activation was dependent on the
generation of ROS. Hyperoxia has been shown to generate intracellular production of O2and H2O2 by the mitochondria (Freeman & Crapo, 1981). Another study done by Pagano,
et al (2004) focused on the role of cytochrome c (a cell death promoting factor) in the
alveolar cell death seen during hyperoxia in a rat model. Hyperoxia induces high
amounts of cytochrome c to be released from the mitochondria into the surrounding
cytosol. Their study revealed that by blocking the mitochondria from releasing
cytochrome c through administration of cyclosporine A, lung tissue could be protected
from damage during hyperoxia treatments. While the exact biological events are not yet
fully understood it is apparent that mitochondria play an integral role in hyperoxia
induced cell death. It is witnessed by several studies that hyperoxia has an exacerbating
effect on antioxidant defense systems. The toxic nature of excess free radicals can result
in a multitude of damaging effects such as apoptosis, mitochondrial dysfunction,
increases in harmful enzymes, and structural changes.
Linking Hyperoxia and Precipitation of AD
A study done by Shua-Haim, et al (1998) suggested a link between surgery in the
elderly and precipitation of AD. The study reported an acute onset of AD post-surgery.
The acute onset is in constradiction to the definition by the NINCDS-ADRDA that states
the onset of AD is gradual. This suggests that the patients may have been suffering from
a “pre-clinical” form of AD prior to the surgery. The surgery including all of the
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treatments surrounding surgery resulted in a rapid neurological degeneration and
subsequent diagnosis of AD. This study suggests that some aspect of surgery or postsurgical care may act as a risk factor in aged individuals.
Along this line, a study was done by Newman, et al (1995) investigating a number
of factors surrounding surgery and their predictive value for cognitive decline. The study
revealed that the strongest predictor of cognitive decline post surgery is age. The mean
arterial pressure (MAP) was also examined, and the study revealed that in older patients
MAP may play a role in post-surgery cognitive decline. Also they looked at the
apolipoprotein E-έ4 allele, the gene variant associated with the sporadic form of AD, as a
genetic predictor. They found a significant association between the presence of the
apolipoprotein E-έ4 allele in patients who had declines in cognitive performance postsurgery. This evidence further point towards the exacerbating effects that surgery has on
patients who may be at a higher risk for developing AD.
Surgery involves numerous components including anesthesia, administration of
numerous drugs, changes in blood pressure, and possible exposure to hyperoxia postsurgery. Studies trying to tease out one variable as being the causative agent for the
cognitive deterioration are difficult as the typical surgery incorporates many complicating
factors. Several studies have attempted to isolate the effects of anesthesia. A recent
retrospective hospital-based case-control study done by Gasparini, et al (2002) reported
finding no association between exposure to anesthesia and development of AD. The
study examined 115 AD patients’ hospital records for exposure to anesthesia and found
that the exposure to anesthesia 1 and 5 years prior to disease onset was not correlated to
future development of AD. An older study done by Bohnen, et al (1994) further
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supports their findings. In a retrospective, population based, case-control study they
looked at the exposure of 208 AD patients and found that it is unlikely that even multiple
exposures to anesthesia increases the risk of developing AD. However, the same authors
also reported that the age at which an individual was exposed to and extent of anesthesia
given may play a more important role. The study investigated the cumulative exposure to
anesthesia for more than 40 years prior to onset of AD, and found that the age of AD
onset was inversely related to the cumulative exposure to anesthesia before the age of 50.
The authors suggest that the onset of AD may be related to exposure to anesthesia at a
relatively earlier age.
Blood pressure has also been investigated with conflicting findings. At study
done by Moller, et al (1998) reported that hypotension (abnormally low blood pressure)
was not a significant risk factor in predicting cognitive dysfunction post-surgery.
However, recent work by Dr. T. Monk (personal communication) has suggested that
hypotension can be extremely dangerous to a patient during surgery. Dr. Monk
conducted a study in which he found that for every minute that a patients’ systolic blood
pressure dropped below 80 mmHg there was a 4% increase in the chance of death within
one year post-surgery. These findings are very alarming, as they point towards the
extremely dangerous nature of hypotension during surgery. It also points towards the
irreversible effects that hypotension exerts on the body. Hypotension can result in a state
of hypoperfusion in the brain. The steep drop in blood pressure results in a decrease of
oxygenated blood being available to adequately sustain the metabolic demands of the
brain. Patients that exhibit hypotension during surgery are given treatments with
hyperoxia post-surgery in order to boost a patients’ blood oxygen saturation (J. Robert,
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personal communication). He hypothesizes that hypotension alters the bodies
inflammatory response. Treatment with anti-inflammatory agents post surgery has been
found to reduce the number of deaths seen 1 year post surgery.
Hyperoxia treatments are frequently given to patients post-surgery to increase the
oxygen content of blood, but it also acts as a potent cerebrovasoconstrictor resulting in
decreased cortical blood flow (Rostrup et al, 95). As a vasoconstrictor, it is plausible
that treatments with hyperoxia could also result in a hypoperfusion of the brain.
Hyperoxia exposure alone has not been shown to have deleterious cognitive effects as
discussed in several studies above. However, the studies conducted looking at its effects
were done on either young individuals or individuals not proven to be at risk for
developing AD. The evidence presented above linking surgery and precipitation of AD
alongside the knowledge that hyperoxia has the potential to cause a variety of toxic side
effects has provoked a study to be conducted investigating hyperoxia as a potential
causative agent of cognitive impairment in aged individuals post-surgery, who have
subclinical AD.

Specific Aims
Hyperoxia has been proven to generate free radicals (O2-) thereby inducing
oxidative stress, confer structural damage in nerves, upregulate enzymes responsible for
cellular death, peroxidize membranes, and decrease cerebral blood flow. These
deleterious effects have been discovered using both human and animal models that had
compromised/immature antioxidant defense systems such as those seen in the studies
using infant models or in the human studies using patients with traumatic brain injuries.
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Oxidative stress is one of the primary pathological mechanisms underlying AD. As
mentioned earlier, oxidative stress plays a critical role in the early stages of the disease;
perhaps, paving the way for more severe neuro-degeneration (Pratico & Sung, 2004).
An increased level of Aβ (both soluble and insoluble) is also one of the primary
pathological mechanisms underlying AD. Aβ has been shown in the numerous studies
mentioned above to act as a vasoconstrictor and as a generator of free radicals. Both Aβ
and hyperoxia are capable of generating superoxide radicals, causing cerebrovascular
constriction, thus decreasing cerebral blood flow (brain hypoperfusion). I propose that
hyperoxia treatments given to cognitivel- normal APP/PS1 transgenic mice will work in
combination with their brain Aβ to markedly increase production of superoxide radicals,
causing oxidative stress damage to brain tissue and result in cerebrovascular constriction
with subsequent cerebral hypoperfusion. I propose that the damage done by the increase
in oxidative stress and cerebral hypoperfusion will result in cognitive impairments.

In this study I specifically propose to expose Alzheimer’s transgenic mice to several
hyperoxia treatments and to:
1) Assess the cognitive function of the mice before and after
hyperoxia treatment in the Radial Arm Water Maze task
of working memory
2) Measure the amount of oxidative stress incurred through
examination of markers of lipid peroxidation in specific
brain regions
3) Quantify brain Aβ loads, both diffuse and compact
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4) Perform neurodegenerative cell staining in specific
hippocampal regions
5) Perform correlation analyses examining any possible
relationships between pathological, neurochemical, and
behavioral measures.

Materials and Methods
Animals
A total of 20 mice were utilized during the course of this study. All mice
contained a mixed background of 56.25% C57, 12.5% B6, 18.75%SJL, and 25.5% Swiss
Webster. The animals genotypically fall into one of three categories; nontransgenic,
double transgenic (containing both the APP/PS1 mutations), and single transgenic
animals (containing the APP mutation only). All of the mice were bred from a cross
between a P (parental generation) heterozygous male mouse carrying the mutant
APPK670N, M671L gene with a F1 PS1 (transgenic line 6.2) female mouse to obtain the F2
generation including APP/PS1, APP, PS1, and non-transgenic mice. After weaning, the
mice were genotyped and singly housed in cages with rodent chow and water ad libum.
Mice were maintained in a 10 hour dark 14 hour light cycle, with all behavioral testing
done during the light cycle. After the initial round of pre-treatment RAWM testing,
transgenic animals were broken into two behaviorally-balanced groups; the hyperoxia
group (O2) and the control group (air). As shown in Table 1, the group of transgenic
mice that were exposed to hyperoxia consisted of 3 APP/PS1 mice and 2 single
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transgenic APP mice. Pre-treatment performance of the 3 double transgenics and the 2
single transgenic mice was found to be nearly identical, and thus clearly not significant
different (p= 0.7 for overall T4 and T5). The control group of animals that were exposed
to compressed air consisted of 6 APP/PS1 mice, whose behavior was statistically similar
to the hyperoxia group (determined by analysis of pre-treatment behavior). A total of 8
non-transgenic mice were used as behavioral controls and were not exposed to either
hyperoxia or air treatment. For the biochemical portion of the experiment, the same 8
non-transgenic mice were used as controls (Table 1). Also the same group of 6 APP/PS1
control (air exposed) mice were used as the control group in the biochemical portion of
the experiment. The hyperoxia group of animals consisted of 4 APP/PS1 mice. The
addition of the extra mouse as compared with the group of 3 APP/PS1 mice used in the
behavioral portion is explained due to the fact the fourth mouse was deleted from the
behavioral portion of the study. The animal was deleted due to the fact that it was
statistically determined to be an outlier after completing the mid-point portion of
behavioral testing. The 2 APP animals exposed to hyperoxia were not included in the
biochemical portion of the study due to genotype differences.

Genotype & Treatment

Behavior

Biochemical

Non-Transgenics

8

8

APP/PS1 Controls (Air)

6

6

APP/PS1 O2

3

4

APP O2

2

0

Table 1. Animals included in the behavior and biochemical portions of the study.
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General Protocol
At 3 months of age, 9 APPsw+PS1, 2 APP transgenic mice and 8 non-transgenic
littermates were pre-tested in the radial arm water maze (RAWM) task of working
memory for 15 days. The transgenic (Tg+) mice were then divided into two groups
balanced in cognitive performance from the RAWM pre-test. One group of Tg+ mice
were exposed to 100% oxygen for 3 hours. The remaining Tg+ mice received the same
treatment, except that normal air flowed through the gas chamber. The non-transgenic
mice were not exposed to any treatment. Beginning three days following gas treatment,
all animals were re-tested in the RAWM task for 15 days, with the two groups of Tg+
mice showing no differences in performance. At 5½ and 7 months of age, all animals
received a second and third gas treatment, respectively. Final RAWM testing for 9 days
was begun three days after the 3rd gas treatment. At the completion of testing, all mice
were euthanized and their brains processed for: 1) Aβ staining with 6E10 antibody and
Thioflavin S, 2) degenerative neuronal numbers (acid fuchsin/toulidine blue staining), 3)
lipid peroxidation markers (Iso-Furans and 8-IsoProstane), and 4) hippocampal APP,
APOE, COX-2, and GFAP levels.
1st RAWM
Testing

Animals Born

0

1

2

3

2nd RAWM
Testing

4

5

1st gas
treatment

6

2nd gas
treatment

Fig.1. General protocol time line for the hyperoxia study.
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3rd RAWM
Animals
Testing
Sacrificed

7

3rd gas
treatment

8

9

Hyperoxia
All animals were food-deprived for 24 hours prior to O2 gas insult. For gas
treatments, a multi-chambered apparatus was constructed of plexiglass with input valves
allowing for the flow of 100 % oxygen/compressed air into the chamber. For all gas
insults, airflow per minute was regulated by a flow meter and maintained at 1.5x chamber
volume. Treatments were conducted under isobaric conditions. Bara-Lyme was used in
each chamber to control for excess CO2. Each gas treatment was administered for 3
hours. The control gas treatments were conducted in the same manner as the hyperoxia
with the exception that compressed air (20% O2) was utilized. All animals received a
total of three treatments, administered at approximately 6 week intervals (Fig. 1). The
first treatment was given when the animals were 4 months of age. The second treatment
was given at 5.5 months of age and the last treatment was given at 7 months of age.
Behavioral Assessment
Spatial working (short-term) memory was assessed in the radial arm water maze
task (RAWM). The task is conducted in a 100-cm diameter inflatable pool with an
aluminum insert. The aluminum insert creates 6 radial swim arms (30.5 cm length x 19
cm width), with each swim arm radially distributed in the pool from a central circular
swim area 40 cm in diameter. The insert extended 5 cm above the surface of the water.
The water was maintained at 23-27° Celsius. A transparent escape platform (9 cm
diameter) was placed in one of the arms, submerged 1.5 cm below the surface of the
water. Around the perimeter of the pool and on an adjacent wall visual/spatial cues were
placed. The visual cues consisted of large brightly colored objects distinct in shape. For
example, the visual cue located at the end of arm 2 was a suspended beach ball, and the

58

visual cue at the end of arm 6 was a small closed umbrella. The visual cues were used by
animals to orient themselves within the maze and facilitate finding the escape platform.
On each day of testing, the animals were given five 1 min. trials. Each trial lasted for 1
minute, with a 30 second delay between trials 1-4 (during which the mouse remains on
the platform), and a 30 minute delay between trials 4 and 5. Trials 1-4 are acquisition
trials in which the animals are learning the location of the escape platform for that day.
The last of four consecutive acquisition trials (trial 4, T4) and the delayed retention trial
(trial 5, T5) are indices of working memory. On any given day, the escape platform
location is placed at the end of one of the six swim arms. The platform location was
moved daily to a different arm in a semi-random fashion. By moving the escape
platform, the animal must learn a new location of the platform daily and rely on working
memory rather than long-term memory. On each day, different start arms for each of the
five daily trials were also selected in a semi-random fashion that incorporated all five
arms. At the beginning of any given trial, the mouse was placed into the start arm facing
the center of the pool and given 60 sec. to find the platform, with a 30 sec stay. For each
trial, the latency (amount of time in sec) and number of errors to find the submerged
platform in the goal arm were recorded. An error was recorded when an animal swam
into an arm that did not contain the escape platform. Each time an animal made an error,
the researcher gently pulled the animal out of the wrong arm and guided the animal back
into the start arm. If the animal failed to make an arm choice for 20 sec, or if the animal
entered the platform-containing arm but failed to locate the platform, then an error was
also recorded and the animal was brought back into the start arm for that trial. An error
of 4.4 was given to any animal that did not make at least three choices during a given trial
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for the pre-treatment test point. An error of 7.4 was given to any animal that did not
make at least three choices during a given trial for the post-treatment test point. The
numbers 4.4 and 7.4 were calculated by averaging errors for all animals that did not
locate the platform for block 1 (day 1-day 3) on trial 1 (T1). The animals were tested at
three different time points: before treatment (15 days), mid-treatment (15 days), and posttreatment (9 days).
Brain Collection and Dissection
Following the third and final behavioral testing in the RAWM, animals were
deeply anesthetized with pentobarbital (100mg/kg) and perfused with 100ml of 0.9%
saline. Post mortem brains were immediately removed and bisected sagitally. The left
hemisphere was fixed in 4% paraformaldehyde. The right hemisphere was chilled in cold
saline for 1 minute and then dissected into 5 major brain regions; cerebellum, anterior
cortex, striatum, posterior cortex, and hippocampus. The individual brain regions were
transferred into individual 1.5 ml Eppendorf tubes and then were quick frozen at -80°C
on dry ice for biochemical analyses. The left hemisphere was stored in 4%
paraformaldehyde overnight (12 hrs) and then transferred to a graded series of sucrose
solutions (stored continually at 4°C) beginning at 10% and finishing at 30%, where
tissues remained until sectioning. Tissues were coronally sectioned on a sliding
microtome at 25 µm for Aβ immunohistochemistry and histology.
Histological Analysis
Acid Fuchsin/Toulidine Blue Staining. Degenerative neurons were stained using a
combination of acid fuchsin and toulidine blue staining. Acid fuchsin is an anionic dye
that strongly stains the nuclei and cytoplasm of necrotic neurons due to high levels of
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proteins rich in arginine and lysine (Kiernan et al., 1998; Victorov et al., 2000). The
acidophilia, or strong attraction to acidic dyes, is considered to be a hallmark of neuronal
damage and death that may be due specifically to brain ischemia. Toulidine blue is a
basic metachromatic stain that stains nuclei dark blue and cytoplasm light blue and serves
to intensify staining. Degenerative cells have an irregular atrophied shape and a much
darker stain, denoting the acidophilia associated with degeneration. To begin staining, 25
µm coronal sections of brains stored at 4° C in PBS (including hippocampal regions)
were mounted on gelatin prepared slides. The slides were brought through a standard
rehydration scheme beginning with xylene and progressing from 100% EtOH to 40%
EtOH and finishing in two water baths. Rehydrated sections were then dipped in 1% acid
fuchsin solution for approximately 35sec. The acid fuchsin stained slides were washed
twice in water and then dipped in toluidine blue solution for approximately 45 sec and
rewashed in two water baths. After air drying, slides were coverslipped for microscope
analysis.
The first analysis performed (semi-quantitatively) scored the degree of cell
degeneration in the dentate gyrus associated with the dorsal hippocampus. For any given
animal, 5 sections (spaced at least 75 µm apart) were scored using a scale of 0-4 and
averaged. In the scale, 0 represents an animal with only 1-2 degenerative cells visible
along the superficial granule cell layer, 1 represents an animal with 3-6 sporadic cells
along the superficial granule cell layer, 2 represents 7-15 degenerative cells along the
superficial layer, 3 represents lines of degenerating cells along the superficial layer, and 4
represents an animal with lines of degenerating cells along the superficial granule cell
layer alongside clusters of degenerating cells penetrating deeper layers. Analyses were
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conducted blind to genotype and treatment at 20x magnification on a Zeiss MC-63A
microscope. Degenerative cell counts were performed in the CA1&2, CA3, and CA4
regions of the dorsal hippocampus. All counts were done on 5 representative sections
(spaced at least 75 µm apart) per animal and averaged.
6E-10 & Thioflavin S staining. Staining with the 6E-10 antibody detects both
compact and diffuse Aβ plaques.

In brief, 25µm sections were mounted on pre-treated

slides and processed through standard heat induced epitope retrieval steps beginning in
25mM citrate buffer (pH 7.3). Sections were incubated overnight at 4°C with the
primary antibody; an anti- Aβ antibody (6E-10 purchased from Signet) diluted 1:2500. A
secondary antibody, anti-mouse IgG was used and sections were developed with a
NovaRed (Vector) substrate kit. Slides were then brought through a dehydration scheme
(beginning with water proceeding through graded series of alcohols and ending in a 5 sec
xylene dip). Finally slides were coverslipped with a xylene-based mounting media for
microscope analysis.
Thioflavin S staining was used to only detect compact (dense) Aβ deposits.
Sections (25 µm) mounted on gelatin dipped slides were immersed in 1% Thioflavin S in
50% EtOH for 5 minutes. Sections were then immersed in graded alcohols, followed by
xylene, and coverslipped for microscope analysis.
Image Analysis. All data collected from the 6E-10 and Thioflavin-S staining was
analyzed on a Nikon Eclipse E1000 microscope using either 4x (Thioflavin S) or 10x
(6E-10) Plan Flour objective lenses. Images were captured using a Retiga 1300 CCD
with a QImaging RGB LCD-slider. For the thioflavin S staining, a Nikon BV-2B
fluorescence filter cube was used. Data from both of these stains was obtained from three
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equally spaced coronal sections through the dorsal hippocampus including the overlying
parietal cortex. Image analysis was performed using customized software written in
Visual Basic 6.0 (Microsoft) that used Auto-Pro function calls to segment and quantify
images according to the established protocols used by Costa et al (2004). Aβ deposition
was quantified as a percent of area of interest (=Area stained total/Area Measuredtotal).
Neurochemical Analysis
Lipid Peroxidation Measures. Isofurans and 8-isoprostanes are stable byproducts of lipid peroxidation and were assayed in post-mortem brain tissue of the Tgand double transgenic (APP/PS1) mice. The anterior and posterior cortices were sent to
Dr. J. Roberts at Vanderbilt University for analysis. Briefly, isofurans and 8-isoprostanes
were quantified by stable isotope dilution gas chromatography/negative ion chemical
ionization mass spectrometry as decribed by Fessel et al. (2003).
Protein Markers. Protein level expression was assessed using western blot
analysis for several proteins including: APP, APOE, COX-2, and GFAP. Tissue samples
from the hippocampus were homogenized in 10mM sodium acetate buffer pH 7.2
containing 0.1% triton X-100 and mammalian protease inhibitor cocktail (Sigma
Chemical). Samples were then centrifuged and adjusted to contain identical protein
concentration based on the Lowry protein assay. The remaining homogenate was
electrophoresed over 4-20% gradient polyacrylamide gels and transferred to
polyvinylidene difluoride membranes. Blots were visualized using antibodies specific to
each protein, and developed with chemilumiscence detection using horseradish
peroxidase-conjugated secondary IgG. Gross differences in expression level were
determined by visually comparing blot sizes.
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Statistical Analysis
Behavioral Analysis. A total of three sets of behavioral data were collected from
the three rounds of RAWM testing. Before statistical analysis of the behavioral data, the
data was divided into 3 day blocks to aid in data presentation. Any outliers or nonperformers (animals who display consistent behavior inhibiting proper performance)
were eliminated from the behavioral statistical analysis. The statistical analysis included
only those animals with a full data set (e.g., completed all behavioral testing); as the
animals that died during the course of the study were eliminated from all behavioral
analyses. The RAWM behavioral measures were analyzed with both one-way ANOVAs
and two-way repeated measure ANOVAs. Following ANOVA analysis, post-hoc pairby-pair differences between groups were determined through the Fisher LSD test.
Differences between groups were considered significant at p<0.05. Paired T-tests were
performed to determine if there were any changes in each group’s pre- vs. post-treatment
behavior.
Histological/Biochemical. Pathological data analysis from the histological and
biochemical portion of the experiment was performed using ANOVA followed by
Fisher’s LSD post-hoc test. Correlational analyses were conducted using the Systat
analytical software package. Correlations were done between behavioral data and the
histological/biochemical data to determine if any relationships exist.
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Results
Behavior
Pre-Treatment Testing. In pre-treatment RAWM testing (Figs. 2 and 3), both
Tg+ and Tg- mice performed similarly as evidenced by no overall group effect across all
5 blocks for working memory Trials 4 [F(1,17)=0.21, p=n.s.] and Trial 5 [F(1,17)=0.27,
p=n.s.]. Animals in both groups collectively showed improved working memory across
all 5 blocks of testing, as indicated by highly significant block effects for both Trial 4
[F(4,68)=3.86, p<0.01] and Trial 5 [F(4,68)=10.83, p<0.00001). At individual blocks,
the only significant group difference occurred during Block 2, Trial 5 of testing. During
the last three blocks of testing, however, Tg- and Tg+ mice were identical in working
memory performance (Fig. 2). Across all 15 days of testing, Tg+ and Tg- mice were both
able to reduce their “overall” number of errors between the first semi-random trial (Trial
1) and working memory Trials 4 and 5 (Fig. 3). Thus, Tg+ and Tg- mice exhibited
similar working memory performance during pre-treatment testing, with both groups able
to improve performance across trials and across blocks of testing. When animals in the
Tg+ group were assigned to receive hyperoxia or air treatments, the pre-treatment
performance of these two sub-groups was identical. Even comparing pre-treatment
performance between the 3 APPsw+PS1 and 2 APPsw mice comprising the future
hyperoxia group, there were no differences in working memory.
Mid-Treatment Testing. There were no differences in working memory
performance between Tg+Con and Tg+O2 treatment groups overall or during individual
blocks of performance for either T4 or T5 (data not shown).
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Post-Treatment Testing. Over the 3 blocks of post-treatment testing (Figs. 4 and
5), there was a significant group effect for Trial 5 [F(2,16)=3.56; p≤0.05], with post hoc
analysis indicating that Tg+O2 mice (but not Tg+Con mice) had impaired T5 working
memory vs. Tg- controls (p<0.02). The group effect for T4 approached significance
[F(2,16)=2.45, p=0.11] with post hoc analysis again showing impairment of Tg+O2 mice
vs. Tg- controls (p≤0.05). Closer inspection of individual blocks (Fig. 4) revealed a
consistent trend for Tg+O2 mice to have the greatest number of T4 and T5 errors such
that, when overall T4 and T5 performance was analyzed (Fig. 5), significantly greater
numbers of working memory T4 and T5 errors were evident for the Tg+O2 group vs. Tgcontrols. Performance of Tg+Con mice consistently fell between the Tg+O2 and Tggroups, indicating a non-significant trend for impairment. The impaired working
memory of Tg+O2 mice is underscored by comparing overall T1 vs. T5 for each group
(Fig. 5). Both the Tg- and Tg+Con groups showed a significant reduction in errors from
T1 to T5 (p<0.00001 and p<0.005, respectively), demonstrating good working memory.
By contrast, Tg+O2 mice could not significantly reduce their overall number of errors
between T1 and T5 (p=n.s.). As was the case for pre-treatment testing, there was no
difference in post-infusion performance of the 3 APP+PS1 mice vs. the 2 APP mice that
comprised the hyperoxia treatment group (data not shown). Swim speed analysis (the
number of seconds per error made) revealed that there were no significant differences
between groups in swim speed (data not shown.
Pre – vs. Post-Treatment
To further elucidate any changes in working memory performance resulting from
gas treatment, each group’s pre-treatment RAWM performance (overall T5 errors) was
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compared to their post-treatment performance (Fig. 6). Tg- mice showed a nearlysignificant (p<0.09; paired t-test) decrease in post-treatment T5 errors, while Tg+Con
mice exhibited stable pre- vs. post-treatment performance. In sharp contrast, Tg+O2
mice made significantly more T5 errors during post-treatment testing (p<0.05). The
poorer working memory performance of Tg+O2 mice during post-treatment testing is
further exemplified by examining the pre- vs. post-treatment performance of individual
animals for all three groups (Fig. 7). The vast majority of animals in the Tg- and Tg+Con
groups showed improved or stabilized performance during post-treatment testing, while
four of the 5 Tg+O2 mice exhibited poorer post-treatment performance.
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Pre-Treatment

Tg Tg +
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*
5

Errors
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3

2

1

0

T1

T4 T5

B1

T1

T4 T5

T1

T4 T5

B3

B2

T1

T4 T5

B4

T1

T4 T5

B5

Fig. 2. RAWM pre-treatment acquisition (T1-T4) and memory retention (T5) in Tg+
mice and Tg- mice over five 3-day blocks. * = significant difference between Tg- and
Tg+ (p<.025) indicating an impairment selectively in Block 2 (B2) in working memory
(T4 & T5) for the Tg- group. Otherwise, no other group differences were seen, especially
in the last 3 blocks (B4 & B5) indicating similar working memory in the Tg- and Tg+
groups during pre-treatment testing.

68
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T1 T4 T5
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Fig. 3. Pre-Treatment acquisition (T1-T4) and memory retention (T5) overall errors (5
block average) in Tg- and Tg+ mice. Both groups of mice display the ability to
significantly reduce their number of errors from T1 to T4 and T5. * p<.04 or higher level
of significance for both groups vs. T1.
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Fig.4. RAWM post-treatment working memory in Tg-, Tg+Con and Tg+O2 mice over
three 3-day blocks. * = significant difference between Tg- and Tg+O2 (p<.02). During
working memory trials 4 & 5 a trend for the Tg+O2 group to make more errors than
Tg+Con mice vs Tg- is particularly evident during the first two blocks.

70

Post-Treatment
TgTg+Con
Tg+O2

7

Overall Errors

6
5

*

4

**

3
2
1
0

T1

T4

T5

Trials

Fig.5. Overall RAWM post-treatment working memory performance across 9 days of
testing. Tg+O2 mice were significantly impaired in comparison to Tg- mice during both
T4 overall (* p≤ .05) and T5 overall (** p< .02). Tg+Con mice remained unimpaired.
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Fig.6. RAWM pre- vs. post-treatment overall T5 Errors for the Tg-, Tg+Con, and Tg+O2
groups. * p< .05 (paired t-test) pre-treatment vs. post-treatment overall T5 errors in the
Tg+O2 group. Both the Tg- and Tg+Con group displayed a trend to reduce their number
of errors from the pre- to post-treatment time points.
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Fig.7. Individual plots of pre- vs. post-treatment overall T5 errors for all animals in each
group. All of the animals in the Tg+O2 group (with the exception of one that stabilized)
are shown to increase their number of overall T5 errors.
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Neuropathology and Neurochemistry
Degenerative Neuronal Counts. To determine any effects of transgenicity and/or
treatment on the number of neurodegenerative neurons in hippocampus, the acid
fuschin/toluine blue method for identifying such neurons was used. As shown in Figure
8, there were no effects of transgenic or hyperoxia treatment on mean numbers of
degenerative neurons in CA1&2, CA3 and CA4 hippocampal regions. Utilizing a scale
of 0 to 4, semi-quantitative analysis of neurodegenative neuron numbers in dentate gyrus
also yielded no effects of transgenic or hyperoxia treatment (Tg-, 1.6±0.3; Tg+Con,
1.1±0.4; Tg+O2, 1.8±0.4). However, correlation analysis revealed a number of
significant associations between hippocampal neurodegenerative neurons and posttreatment working memory in Tg+ mice collectively, irrespective of gas treatment. These
correlations generally involved overall Trial 5 performance, such as the three positive
correlations shown in Fig. 9 between T5 errors and neurodegenerative neuronal
counts/rating in dentate gyrus (p<0.02), CA3 (p<0.05), and CA4 (p<0.02). The
correlation involving CA3 was even more striking if overall T5 “latency” was used
(p<0.005, r=0.861), rather than T5 errors. Thus, high numbers of neurodegenerative
neurons in these hippocampal brain regions were associated with more overall T5 errors.
Neurochemistry. Two novel products of lipid peroxidation, 8-isoprostane and isofurans,
were measured in brain tissue from all three groups. As shown in Table 2, analysis of 8isoprostane revealed no transgenicity or hyperoxia effects in either anterior or posterior
cortex. Although no effect of hyperoxia treatment was also seen for isofurans in either
cortical area, anterior cortex isofuran levels were significantly reduced in both Tg+
groups (Table 2). Correlation analysis between lipid peroxidation measures and working
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memory revealed significant negative correlations between final block T5 performance
and iso-furan levels in anterior cortex (Fig. 9). Animals with higher iso-furan levels in
anterior cortex exhibited better working memory (less errors). This association was
present for Tg+ mice alone, as well as for Tg+ & Tg- mice combined. Although there
were no correlations between lipid peroxidation markers and degenerative neuronal
counts in hippocampus for combined Tg+ & Tg- mice or Tg+ mice alone, several
correlations were present for Tg+ controls alone (n=6). Higher posterior cortex levels of
isofurans were correlated with the number of degenerative neurons in CA1/2 (r=0.858,
p<0.05) and higher posterior cortex levels of 8-isoprostane correlated with the number of
degenerative neurons in the CA3 region. Thus, increased lipid peroxidation in posterior
cortex was associated with higher numbers of hippocampal degenerative neurons.
Preliminary western blots were done investigating the levels of expression of APP, ApoE,
COX-2, and GFAP. Visual analysis of the blots for each of these proteins revealed no
differences in protein expression levels between groups (data not shown).
Brain Aβ Deposition. Immunostaining for diffuse Aβ deposits using the 6E10
antibody indicated that diffuse Aβ loads in neocortex and hippocampus of Tg+ mice were
unaffected by hyperoxia treatments (Fig. 10, upper). Similarly, Thioflavin S fluorescent
staining for compact Aβ deposits also revealed no effect of hyperoxia treatments for
either brain area in Tg+ mice (Fig. 10, lower). Surprisingly few correlations were found
between these two Aβ neuropathology measures vs. working memory, degenerative
neuron counts, and lipid peroxidation markers. Indeed, no correlations were evident
between either Aβ neuropathology measure and any working memory measure or
degenerative neuronal counts in hippocampus. Although no correlations were also found
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between 6E10 staining and lipid peroxidation markers, there was a single significant
correlation involving Thioflavin S: Higher cortical Thioflavin S staining correlated with
higher anterior cortical isofuran levels (r=0.627, p=0.05)
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Fig.8. The mean number of degenerative neurons in various hippocampal regions using
the acid fuchsin and touilidine blue method. No significant differences between groups
were found.
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Fig.9. A series of correlation scatter plots illustrating that the degree of neuronal
degeneration in the dentate gyrus and the number of degenerative neurons in, CA3, and
CA4 region of the hippocampus were positively correlated with working memory
impairment in Tg+ mice, irrespective of gas treatment. More degenerative neurons were
seen in Tg+ mice making high numbers of working memory (Trial 5) errors overall.

78

Lipid Peroxidation Markers
Tg-

Tg+Con

Tg+O2

8-IsoProstane(ng/g)
Anterior Cortex

3.4 ± 0.3

3.1 ± 0.3

3.2 ± 0.4

Posterior Cortex

3.9 ± 0.9

3.4 ± 1.0

5.0 ± 1.3

Anterior Cortex

6.5 ± 1.0

3.2 ± 1.1

2.5 ± 1.4

Posterior Cortex

8.7 ± 3.1

4.5 ± 3.6

9.4 ± 4.4

Iso-Furans(ng/g)

*

*

Table 2. The mean amount (results presented as ng/g wet weight of tissue) of 8IsoProstane and Iso-Furan, both markers of lipid peroxidation, in anterior cortex and
posterior cortex from each group of animals. Lipid peroxidation in neocortex was
unaffected by hyperoxia treatments in Tg+ mice, although anterior cortex isofuran levels
were significantly reduced in both groups of Tg+ mice. * = p<0.05 vs. Tg- for iso-furan
measurement in the anterior cortex.
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Fig.10. A pair of correlation scatterplots illustrating that an inverse correlation was
present between iso-furans in anterior cortex and working memory for Tg+ mice (left), as
well as for combined Tg- and Tg+ mice (right). Mice with higher iso-furan levels
actually had better working memory (made less errors) than those with lower iso-furan
levels.
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Fig.11. Aβ loads in neocortex and hippocampus of Tg+ mice were not affected by
hyperoxia treatments. Hyperoxia had no significant effect on Aβ deposition in either
brain region, as determined by both 6E10 immunostaining and Thioflavin-S staining.
Brains from Tg- mice exhibited no staining with either method.
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Discussion
General Summary. In the present study, we evaluated the effects of hyperoxia on
AD transgenic mice in the RAWM. We determined that exposures to 100% oxygen
(hyperoxia) trigger working memory impairment in Tg+ mice that otherwise would have
been unimpaired. Hyperoxia induced memory impairment in Tg+ mice did not involve
changes in brain Aβ deposition, degenerative cell numbers in hippocampus, neocortical
lipid peroxidation, or hippocampal levels of APP, ApoE, COX-2, or GFAP.

The

combination of excess Aβ and hyperoxia could have induced greater cerebral
vasoconstriction than either one alone, resulting in a pathologic cerebral hypoperfusion
that triggered subsequent cognitive impairment. These results suggest that humans
genetically pre-disposed to AD and those with increased brain Aβ levels have increased
risk of developing cognitive impairment following hyperoxia treatment. This is a novel
finding that calls into question the wide use of 100% oxygen treatments in aged
individuals at high risk for developing AD following major surgery.
Behavior. In pre-treatment RAWM testing at 3 months of age, Tg- and Tg+ mice
were identical in working memory performance. Both groups were able to reduce errors
from T1 to T4 and T5. Therefore, the Tg+ animals were not impaired in working
memory at 3 months of age (no overt plaque deposition). Post-treatment RAWM testing
at 7.5 months of age revealed a cognitive impairment selectively in the Tg+O2 group vs.
the Tg- group in overall errors for both T4 and T5. The Tg+Con group trended towards
impairment, however, remained non-significant. The data shows this consistent trend
through all 3 blocks of post-treatment testing, where the Tg+Con group consistently
made more errors than the Tg- and less errors than the Tg+O2 group. The three
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hyperoxia treatments given to the Tg+ mice induced an earlier cognitive impairment in
animals that would have otherwise remained unimpaired. This is evidenced by the fact
that the Tg+Con group of animals (littermates of the Tg+O2 group) were not impaired (as
compared with the Tg- group) at the post-treatment test point.
In comparing pre- vs. post-treatment behavior in the three groups of animals the
effect of hyperoxia becomes even more apparent. While both the Tg- and Tg+Con
groups either stabilize or improve their performance in overall T5 errors from pre- to
post-treatment testing the Tg+O2 group significantly increased their number of errors
from pre- to post-treatment testing. The behavioral finding, that hyperoxia induces
impairment in rodents has been reported on previously in a publication by Fukui, et al
(1999). In that study the authors exposed a rat model for oxidative stress (rats were fed a
vitamin E deficient diet) to 48 hours of hyperoxia and tested cognition and memory in the
Morris water-maze. They reported that the animals exposed to hyperoxia were not
capable of “relearning”, and although the testing methods were somewhat questionable,
their findings that hyperoxia had a negative effect on behavior corroborates the findings
of the present study. As far as the knowledge of this laboratory permits this is the only
study investigating the effects of hyperoxia in a rodent model for behavior.
Studies done with humans and hyperoxia have reported that hyperoxia has a
beneficial effect on short-term memory in normal adults. In 1998 a study done by Moss
et al., (1998) reported significant improvements in immediate and delayed word recall in
individuals exposed to hyperoxia for 1 or 3 minutes prior to the start of testing. A study
done by Scholey et al., (1999) reported that individuals exposed to hyperoxia for 1
minute prior to testing recalled more words and had faster reaction times. These studies,

83

alongside other similar studies (Prior & Chander 1982 & Sholey et al., 1998) suggest that
hyperoxia may be beneficial to short-term memory when administered directly prior to
testing. It is important to note that these studies are only tangentially related to the
current study. The long term effect of hyperoxia was not investigated in any of these
studies, and more importantly the studies utilized young healthy adults as the test
subjects. Only one study done by Prior & Chander (1982) investigated the effects of
hyperoxia in elderly patients. In that study the researchers exposed elderly patients to 12
hours of post-surgery hyperoxia and then performed cognitive testing immediately
following the treatment. This study reported that the hyperoxia exposure did not have a
deleterious effect on cognition. It is important to note that only a single test was given
directly following treatment, with no follow up studies investigating behavioral changes
once the patient returned home. Thus, while previous literature has suggested that
hyperoxia may be either benign or even beneficial under specified narrow conditions, the
long-term effects of hyperoxia given to patients at high risk for developing AD has not
yet been established.
Pathology. Insoluble Aβ was quantified using two staining techniques; antibody
staining for compact and diffuse Aβ deposits was done using the 6E-10 antibody from
Signet, and Thioflavin-S staining was done for compact Aβ deposits. Both staining
techniques yielded no differences between the amount of insoluble Aβ in the Tg+Con
group and the Tg+O2 group. Therefore, hyperoxia does not increase Aβ deposition in the
mouse model utilized in this study. Prior studies using APP models have reported
finding a correlation between Aβ deposition and RAWM performance (Arendash et al.,
2001; Leighty et al., 2004). However, this study did not yield any correlations between
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Aβ deposition and RAWM performance. While the data from the two staining
techniques mentioned above did not show any differences it would be interesting in a
follow up study to quantify soluble Aβ in an ELISA assay. Some evidence has linked
hyperoxia treatment to potentially increasd Aβ production in rodents. A study done by
Wen, et al (2004) found that cerebral ischemia in rats caused a 30% increase in βsecretase activity. The cerebral vaso-constriction caused by hyperoxia would
hypothetically induce mild ischemia, or hypoperfusion in the brain. β-secretase, as
mentioned prior, is the enzyme responsible for the pathological cleavage of APP that
results in the toxic Aβ fragment. Therefore, an increase in production of β-secretase
caused by severe restriction of blood flow to the brain could lead to an increased amount
of deposited Aβ. The expression level of β-secretase would also be interesting to look at
in any possible follow up studies.
The APP/PS1 mouse model utilized in this study has been shown to exhibit the
AD hallmarks of elevated soluble Aβ levels alongside Aβ deposition into compact
plaques by 6 months of age (Takeuchi et al, 2000). Aβ deposition is seen as early as 12
weeks in the cortex and hippocampus of this animal model (Holcomb et al, 1998). The
hippocampus plays a strong role in spatial and memory related tasks, such as the RAWM.
The sensitivity of the task to the hippocampus and Aβ deposition makes the task
extremely fitting for the present study. The present study aimed to use APP transgenic
mice at an age when they were on the verge of displaying cognitive impairments, yet
remained unimpaired. The hyperoxia treatments were designed to push such animals
into cognitive impairment at an earlier age than when the animals naturally would have
developed an impairment. An animal model that is in a state just prior to the onset of
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cognitive impairment models an elderly patient that is in the latent or possibly the
prodromal stage of AD. As mentioned previously, Aβ accumulation and deposition is
thought to occur many years prior to disease diagnosis. Thus, aged individuals at a high
risk for developing AD, have increased amounts of Aβ in their brain. Therefore, the
animal model used exhibits both an imminent decline in cognition alongside the presence
of an abundance of the toxic Aβ protein. The marked decline in working memory in the
Tg+O2 group may therefore, be predictive of what an elderly patient may experience after
being treated with hyperoxia.
Prior literature has suggested a specific vulnerability of the neurons of the
hippocampus to ischemia (Pulsinelli et al, 1985; Kirino et al, 1985). Both Pulsinelli and
Kirino exposed a rat model to 10-30 min. of ischemia (through a 4 vessel occlusion
technique) and found that the neurons in the CA1 region of the hippocampus were
selectively vulnerable to the treatment. Kirino et al, 1985 related two theories explaining
this selective vulnerability. The first theory has been coined the “vascular theory” and
stated that the design of the local vasculature and the location of the hippocampus in the
watershed area between the carotid and vertebrobasilar territories lends the hippocampus
to selective vulnerability due to ischemia. The second theory hypothesized that the
neurons of the hippocampus were selectively vulnerable to ischemia due to differences in
their physical and chemical characteristics. Prior literature has suggested that the
hippocampus is also selectively vulnerable to injury induced by hypoxia (Gorgias et al,
1996). In a study by Gorgias et al. (1996), rats exposed to extreme hypoxia (3%O2) for 6
minutes displayed selective injury to the neurons of the CA1 region of the hippocampus.
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This study suggested that the neurons of the hippocampus, specifically in the CA1 region,
are particularly vulnerable to changes in oxygen availability.
The treatment given in the present study, hyperoxia, is a strong generator of free
radicals as well as a potent vasoconstrictor of cerebral vessels that may result in mild
ischemia. It was therefore, hypothesized that in the present study there would be
evidence of increased neuronal degeneration in the hippocampus in the Tg+O2 group due
to oxidative damage and decreased cerebral blood flow (at least during hyperoxia
treatments). However, acid fuchsin and touilidine blue staining for degenerative neurons
did not reveal any group differences at euthanasia (10 days following final hyperoxia
treatment). Cell counts performed in the CA1/2, CA3 and CA4 regions of the
hippocampus, as well as in the dentate gyrus, did not reveal any differences between the
three groups. Therefore, there was no effect of transgenicity or hyperoxia on
hippocampal neuronal degeneration. Current literature reports no evidence of significant
cell loss in the APP/PS1 model in cortical and hippocampal areas at 3 to 12 months of
age (Takeuchi et al, 2000). Therefore, it was not expected that there should be a
transgenic effect for this histological measure at the 8 month sacrifice timepoint.
Nonetheless, a recent study by Sadowski et al. (2004) reported that in 22 month old
APP/PS1 mice there was a 35.8% dropout of neurons on the CA1 region of the
hippocampus that was detected using stereological techniques. Also, a study by Schmitz
et al. (2004) reported significant hippocampal neuronal loss in 17 month old APP/PS1
transgenic mice bearing both the Swedish and London APP mutations. Perhaps, the
absence of significant hyperoxia effects on neuronal degeneration was due to three 3-hour
hyperoxia treatments being insufficient to induce degeneration detectable by the methods
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used. Or there may have been an increase in degenerative neurons immediately
following hyperoxia that was missed due to the 10 day delay in sacrifice. In future
studies, a more lengthy treatment time and immediate sacrifice should be considered.
Clearly, the hyperoxia-induced cognitive impairment found in this study was not
attributable to hippocampal neuronal degeneration that was detected by acid fuchsin and
touilidine blue staining. However, a more thorough investigation of the cellular integrity
in the hippocampus, or stereological analysis should be performed before this can be
ruled out as a probable cause of the impairment.
It is possible that, with more sensitive techniques a treatment or transgenic effect
on hippocampal neurons may be detectable. For example, it is possible that by using
scanning electron microscopy, changes in cellular morphology (including organelle
integrity) could be identified. A study done by Urano, et al (1997) using a rat model
investigated the morphological changes through electron microscopy in the brain
associated with exposure to 100% oxygen for 48 hours followed by immediate sacrifice.
They found swollen astrocytes around vessels, deformed nerve cell nuclei, swollen
mitochondria, and an abnormal accumulation of synaptic vesicles in swollen nerve
terminals. These cellular changes may be the underlying causes of the cognitive
impairment reported on here.
Correlational analyses of cell count data with RAWM data revealed an interesting
correlation for all Tg+ mice combined. The number of overall T5 working memory
errors was highly correlated with the degenerative cell scoring in the dentate gyrus, and
the mean number of degenerative neurons found in the CA3 and CA4 region of Tg+
animals. Tg+ animals that had a high number of degenerative neurons were found to
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make more overall T5 errors. This correlational analysis provides limited evidence that
the amount of neuronal degeneration in the hippocampus is linked to working memory in
Tg+ animals.
While there is no single measure used to assess the overall level of oxidative
stress in an organism, an assay of iso-furans and 8-isoprostanes (stable by-products of
lipid peroxidation uniquely regulated by oxygen tension) is used to assess the amount of
lipid peroxidation tissue has undergone. Iso-furans, in particular, are increased in
conditions of elevated oxygen concentrations such as that induced by hyperoxia (Roberts
L & Fessel J, 2004). The current study investigated levels of iso-furans and 8isoprostanes in both the anterior and posterior cortices of all animals. There was no
effect of hyperoxia treatment for either marker. As well, there were largely no effects of
transgenicity on these lipid peroxidation markers with one exception. There was
significantly less iso-furan in the anterior cortices of Tg+ animals. This reduction was
somewhat surprising as previous literature has reported increased lipid peroxidation in
AD transgenic animals (Schuessel et al, 2005; Pratico et al, 2001). The study done by
Schuessel et al, (2005) found that in APP transgenic mice, the lipid peroxidation marker
4-hydroxynenal was significantly increased by 3 months of age. The study done by
Pratico et al, 2001 examined isoprostanes (specifically, 8,12-iso-iPF2α –VI) in urine,
plasma, and brain tissue in the APPsw mouse model. The authors reported increases in
isoprostanes universally by 8 months of age, months before overt Aβ deposition in such
mice. Increases in lipid peroxidation in AD transgenic mice may be due in part to the
presence of Aβ. A study by Matsuoka et al, 2001 found that the lipid peroxidation
marker 4-hydroxy-2-noneal (HNE) increases in APP/PS1 mice in relation to an age-
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associated increase in amyloid load between 7 and 30 months of age. This study suggests
a significant role for Aβ in modulating oxidative stress.
Aβ has also been found to generate free radicals (Hensley, 1994). Increases in
free radicals lead to increased oxidative stress with subsequent oxidative damage such as
lipid peroxidation. This fundamental idea coupled alongside the previous literature
provided the foundation for the hypothesis that the Tg+ animals would have increased
levels of the lipid peroxidation markers examined. Our hypothesis that the treatment
group (Tg+O2 ) would have the highest amount of lipid peroxidation incorporates the
increases in oxidative stress previously reported in AD Tg+ animals with the addition of
hyperoxia. Hyperoxia is also a known producer of free radicals, “about 5% of inspired
oxygen is converted to the dangerous superoxide radical” (Fridovich, 1983). Superoxide
as mentioned above was shown in a study by Johnson (2001) to react with NO to form the
toxic peroxynitrite (ONOO-) radical. Peroxynitrite is a potent oxidant that attacks DNA,
proteins, and lipids leading to cellular damage. Thus, the Tg+O2 animals, being exposed
to two sources of increased oxidative stress, were hypothesized to exhibit a heightened
amount of lipid peroxidation markers. However, as mentioned previously, the data
presented here does not support this hypothesis. Our finding that Tg+ animals had
significantly decreased amounts of iso-furan in the anterior cortex may be due to
decreases in brain metabolism. A study done by Sadowski et al, 2004 reported finding
significant decreases in hippocampal glucose metabolism in 22 month old APP/PS1 mice.
Given the fact that glucose metabolism can generate free radicals, a significant decrease
in metabolism could easily explain a decrease in oxidative stress markers. Another
possible explanation for the decrease in lipid peroxidation in Tg+ animals might involve
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the role of Aβ itself. As mentioned previously, there is growing evidence that points
towards the antioxidant capabilities of Aβ, as demonstrated by its ability to prevent
lipoprotein oxidation in the CSF (Kontush, 2001). These findings are in accord with
earlier work that has found Aβ plaque load in humans to be inversely correlated with
oxidative stress, where oxidative damage is quantitatively greatest in the early stages of
the disease and reduces with disease progression (Nunomura, 2001). Thus, decreased
lipid peroxidation in AD brains was associated with increased Aβ deposition. The Tg+
animals may have had decreased lipid peroxidation as compared with non-transgenic
littermates due to the presence of Aβ in their brains. The majority of literature does not
support this idea. However, as the exact role of Aβ has yet to be fully elucidated, it is
relevant to mention this hypothesis that Aβ is acting as an antioxidant as it has not yet
been disproven. In any event, a possible explanation for the lack of a treatment effect
may be simply due to the fact that the animals were sacrificed 10 days post-treatment.
The effects of hyperoxia on lipid peroxidation may therefore be transient. A follow-up
study in which animals are sacrificed immediately following hyperoxia treatment is
necessary to answer this question.
The lipid peroxidation data yielded several interesting correlations when analyzed
alongside the behavioral and cell count data. In Tg+ mice alone, as well as for combined
Tg+ and Tg- mice, higher iso-furan levels correlated with lower T5 errors. Thus, an
animal that performed well in the last block of RAWM testing (exhibited by a low
number of errors) had a higher amount of iso-furan in their anterior cortex. Perhaps,
more cognitively active animals utilize more oxygen resulting in increased iso-furan.
This data suggests that animals with increased iso-furan have better cognition than
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animals with lower levels. In Tg+ control animals alone, a correlation was found
between higher posterior cortex levels of iso-furans and the number of degenerative
neurons in CA1/2; as well, higher posterior cortex levels of 8-isoprostane correlated with
degenerative neurons in CA3. Thus, increased lipid peroxidation in posterior cortex was
associated with higher numbers of hippocampal degenerative neurons in Tg+ untreated
animals. In a yet broader picture, increased degenerative cell numbers in the
hippocampus correlated with both poorer cognitive performance and increased lipid
peroxidation. The exact relationship between these markers is still unclear. More
research needs to be done on these novel markers to discover their underlying function
with regards to memory and cognitive functions.
Vasoactive role of Aβ. Another hypothesis presented in this study focuses on
the vasoactive role of Aβ. Numerous studies (Thomas et al, 1997; Crawford et al, 1998;
Arendash et al, 1999) have reported that freshly solubilized and vascularly injected Aβ
enhances cerebral vasoconstriction in rat models. This enhanced cerebral
vasoconstriction results in decreased cerebral blood flow (Suo et al., 1998). The study by
Suo et al., (1998) utilized fluorescent microspheres to monitor both cerebral blood flow
and cerebrovascular resistance in a rat. This technique could be utilized in a future study
to monitor the effects of hyperoxia on cerebral blood flow. In conjunction with these
murine studies, a human study done by Mentis et al., (1996) reported that PET scanning
techniques show decreases in resting cerebral blood flow in patients with AD. Thus,
patients with an increased amount of Aβ in their brains may have chronic decreased
cerebral blood flow resulting in a hypoperfusion of the brain. It has also been suggested
by Aliyev et al., (2005) that chronic cerebral hypoperfusion may be an initiator of AD.
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Hyperoxia is also a potent cerebral vasoconstrictor (mentioned above). In the present
study, hyperoxia and Aβ may have worked in concert with one another to promote a
greater hypoperfusion than either one alone, resulting in subsequent cognitive
impairment. It would be interesting in a follow-up study to collect data regarding this
hypothesis. During hyperoxia treatment, cerebral blood flow can be monitored using
laser-Doppler flowmetry; this data would be able to provide evidence that the hyperoxia
treatment induces vasoconstriction in AD transgenic mice. In post-mortem tissue, white
matter lesions and the extent of activated microglia and astroglia could be analyzed as
markers of hypoperfusion (Shibata et al., 2004).
Clinical Implications of the Hyperoxia Findings. Currently, two main risk
factors that are widely accepted for developing AD are age and the inheritance of the
ApoE4 allele. Of course, many other risk factors have been put forth involving an
individuals’ health, health history, and lifestyle (discussed above). It has been
previously suggested by Ahua-Haim et al., (1998) that a link between surgery in the
elderly and precipitation of AD exists. Surgery incorporates many potentially harmful
components including administration of various drugs, anesthesia, changes in blood
pressure, and possible perioperative hyperoxia treatments. Results from the present
study suggest that perioperative hyperoxia treatment and a pre-disposition to AD are
additional and synergistic risk factors for AD-related postoperative cognitive impairment.
These findings will hopefully trigger subsequent studies that further elucidate the role of
hyperoxia in patients at risk for developing AD, as well as call into question the wide use
of this potentially toxic treatment.
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